<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC5511775/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511775/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Clinical pharmacology and therapeutics"><meta name="citation_title" content="Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy"><meta name="citation_authors" content="Yiwei Liu, Christian A. Fernandez, Colton Smith, Wenjian Yang, Cheng Cheng, John C. Panetta, Nancy Kornegay, Chengcheng Liu, Laura B. Ramsey, Seth E. Karol, Laura J. Janke, Eric C. Larsen, Naomi Winick, William L. Carroll, Mignon L. Loh, Elizabeth A. Raetz, Stephen P. Hunger, Meenakshi Devidas, Jun J. Yang, Charles G. Mullighan, Jinghui Zhang, William E. Evans, Sima Jeha, Ching-Hon Pui, Mary V. Relling"><meta name="citation_date" content="July 2017"><meta name="citation_issue" content="1"><meta name="citation_volume" content="102"><meta name="citation_firstpage" content="131"><meta name="citation_doi" content="10.1002/cpt.629"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC5511775/?report=abstract"><meta name="citation_pmid" content="28090653"><meta name="DC.Title" content="Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Yiwei Liu"><meta name="DC.Contributor" content="Christian A. Fernandez"><meta name="DC.Contributor" content="Colton Smith"><meta name="DC.Contributor" content="Wenjian Yang"><meta name="DC.Contributor" content="Cheng Cheng"><meta name="DC.Contributor" content="John C. Panetta"><meta name="DC.Contributor" content="Nancy Kornegay"><meta name="DC.Contributor" content="Chengcheng Liu"><meta name="DC.Contributor" content="Laura B. Ramsey"><meta name="DC.Contributor" content="Seth E. Karol"><meta name="DC.Contributor" content="Laura J. Janke"><meta name="DC.Contributor" content="Eric C. Larsen"><meta name="DC.Contributor" content="Naomi Winick"><meta name="DC.Contributor" content="William L. Carroll"><meta name="DC.Contributor" content="Mignon L. Loh"><meta name="DC.Contributor" content="Elizabeth A. Raetz"><meta name="DC.Contributor" content="Stephen P. Hunger"><meta name="DC.Contributor" content="Meenakshi Devidas"><meta name="DC.Contributor" content="Jun J. Yang"><meta name="DC.Contributor" content="Charles G. Mullighan"><meta name="DC.Contributor" content="Jinghui Zhang"><meta name="DC.Contributor" content="William E. Evans"><meta name="DC.Contributor" content="Sima Jeha"><meta name="DC.Contributor" content="Ching-Hon Pui"><meta name="DC.Contributor" content="Mary V. Relling"><meta name="DC.Date" content="2017 Jul"><meta name="DC.Identifier" content="10.1002/cpt.629"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy"><meta property="og:type" content="article"><meta property="og:description" content="Remission induction therapy for acute lymphoblastic leukemia (ALL) includes medications that may cause hepatotoxicity, including asparaginase. We used a genome-wide association study (GWAS) to identify loci associated with elevated alanine transaminase ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511775/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC5511775/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC5511775/pdf/nihms843060.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8DE011DD5A20210000000001A600F7.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5511775%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC5511775</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Clin Pharmacol Ther</a></span>. Author manuscript; available in PMC 2018 Jul 16.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28090653" target="pmc_ext" ref="reftype=publisher&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Clin Pharmacol Ther. 2017 Jul; 102(1): 131–140. </span></a></div><span class="fm-vol-iss-date">Published online 2017 Apr 4. </span> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1002%2Fcpt.629" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1002/cpt.629</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC5511775</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS843060</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/28090653">28090653</a></div></div></div></div><h1 class="content-title">Genome-wide study links <em>PNPLA3</em> variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Liu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879740185408" co-class="co-affbox">Yiwei Liu</a>,<sup>1,</sup><sup>*</sup> <a href="/pubmed/?term=Fernandez%20CA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879784435376" co-class="co-affbox">Christian A. Fernandez</a>,<sup>1,</sup><sup>*</sup> <a href="/pubmed/?term=Smith%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879747693568" co-class="co-affbox">Colton Smith</a>,<sup>1</sup> <a href="/pubmed/?term=Yang%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879745954816" co-class="co-affbox">Wenjian Yang</a>,<sup>1</sup> <a href="/pubmed/?term=Cheng%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879738183552" co-class="co-affbox">Cheng Cheng</a>,<sup>2</sup> <a href="/pubmed/?term=Panetta%20JC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879744436192" co-class="co-affbox">John C. Panetta</a>,<sup>1</sup> <a href="/pubmed/?term=Kornegay%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879744127728" co-class="co-affbox">Nancy Kornegay</a>,<sup>1</sup> <a href="/pubmed/?term=Liu%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879736252704" co-class="co-affbox">Chengcheng Liu</a>,<sup>1</sup> <a href="/pubmed/?term=Ramsey%20LB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879782900800" co-class="co-affbox">Laura B. Ramsey</a>,<sup>1</sup> <a href="/pubmed/?term=Karol%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879740157488" co-class="co-affbox">Seth E. Karol</a>,<sup>3</sup> <a href="/pubmed/?term=Janke%20LJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879742634912" co-class="co-affbox">Laura J. Janke</a>,<sup>4</sup> <a href="/pubmed/?term=Larsen%20EC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879743066464" co-class="co-affbox">Eric C. Larsen</a>,<sup>5</sup> <a href="/pubmed/?term=Winick%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879783150416" co-class="co-affbox">Naomi Winick</a>,<sup>6</sup> <a href="/pubmed/?term=Carroll%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879739987760" co-class="co-affbox">William L. Carroll</a>,<sup>7</sup> <a href="/pubmed/?term=Loh%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879736950160" co-class="co-affbox">Mignon L. Loh</a>,<sup>8</sup> <a href="/pubmed/?term=Raetz%20EA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879744193344" co-class="co-affbox">Elizabeth A. Raetz</a>,<sup>9</sup> <a href="/pubmed/?term=Hunger%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879820460608" co-class="co-affbox">Stephen P. Hunger</a>,<sup>10</sup> <a href="/pubmed/?term=Devidas%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879738428544" co-class="co-affbox">Meenakshi Devidas</a>,<sup>11</sup> <a href="/pubmed/?term=Yang%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879742708960" co-class="co-affbox">Jun J. Yang</a>,<sup>1</sup> <a href="/pubmed/?term=Mullighan%20CG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879746583376" co-class="co-affbox">Charles G. Mullighan</a>,<sup>4</sup> <a href="/pubmed/?term=Zhang%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879742065600" co-class="co-affbox">Jinghui Zhang</a>,<sup>12</sup> <a href="/pubmed/?term=Evans%20WE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879738050208" co-class="co-affbox">William E. Evans</a>,<sup>1</sup> <a href="/pubmed/?term=Jeha%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879736989232" co-class="co-affbox">Sima Jeha</a>,<sup>3</sup> <a href="/pubmed/?term=Pui%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879733512320" co-class="co-affbox">Ching-Hon Pui</a>,<sup>3</sup> and  <a href="/pubmed/?term=Relling%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653" class="affpopup" co-rid="_co_idm139879744317312" co-class="co-affbox">Mary V. Relling</a><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139879740185408"><h3 class="no_margin">Yiwei Liu</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Liu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Yiwei Liu</a></div></div><div id="_co_idm139879784435376"><h3 class="no_margin">Christian A. Fernandez</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Fernandez%20CA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Christian A. Fernandez</a></div></div><div id="_co_idm139879747693568"><h3 class="no_margin">Colton Smith</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Smith%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Colton Smith</a></div></div><div id="_co_idm139879745954816"><h3 class="no_margin">Wenjian Yang</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Yang%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Wenjian Yang</a></div></div><div id="_co_idm139879738183552"><h3 class="no_margin">Cheng Cheng</h3><p>  <sup>2</sup>Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Cheng%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Cheng Cheng</a></div></div><div id="_co_idm139879744436192"><h3 class="no_margin">John C. Panetta</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Panetta%20JC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">John C. Panetta</a></div></div><div id="_co_idm139879744127728"><h3 class="no_margin">Nancy Kornegay</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Kornegay%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Nancy Kornegay</a></div></div><div id="_co_idm139879736252704"><h3 class="no_margin">Chengcheng Liu</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Liu%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Chengcheng Liu</a></div></div><div id="_co_idm139879782900800"><h3 class="no_margin">Laura B. Ramsey</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Ramsey%20LB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Laura B. Ramsey</a></div></div><div id="_co_idm139879740157488"><h3 class="no_margin">Seth E. Karol</h3><p>  <sup>3</sup>Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Karol%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Seth E. Karol</a></div></div><div id="_co_idm139879742634912"><h3 class="no_margin">Laura J. Janke</h3><p>  <sup>4</sup>Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Janke%20LJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Laura J. Janke</a></div></div><div id="_co_idm139879743066464"><h3 class="no_margin">Eric C. Larsen</h3><p>  <sup>5</sup>Maine Children’s Cancer Program, Scarborough, ME</p><div>Find articles by <a href="/pubmed/?term=Larsen%20EC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Eric C. Larsen</a></div></div><div id="_co_idm139879783150416"><h3 class="no_margin">Naomi Winick</h3><p>  <sup>6</sup>Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX</p><div>Find articles by <a href="/pubmed/?term=Winick%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Naomi Winick</a></div></div><div id="_co_idm139879739987760"><h3 class="no_margin">William L. Carroll</h3><p>  <sup>7</sup>Department of Pediatrics, New York University Langone Medical Center, New York, NY</p><div>Find articles by <a href="/pubmed/?term=Carroll%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">William L. Carroll</a></div></div><div id="_co_idm139879736950160"><h3 class="no_margin">Mignon L. Loh</h3><p>  <sup>8</sup>Department of Pediatrics, University of California School of Medicine, San Francisco, CA</p><div>Find articles by <a href="/pubmed/?term=Loh%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Mignon L. Loh</a></div></div><div id="_co_idm139879744193344"><h3 class="no_margin">Elizabeth A. Raetz</h3><p>  <sup>9</sup>Department of Pediatrics, University of Utah, Salt Lake City, UT</p><div>Find articles by <a href="/pubmed/?term=Raetz%20EA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Elizabeth A. Raetz</a></div></div><div id="_co_idm139879820460608"><h3 class="no_margin">Stephen P. Hunger</h3><p>  <sup>10</sup>Department of Pediatrics and the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</p><div>Find articles by <a href="/pubmed/?term=Hunger%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Stephen P. Hunger</a></div></div><div id="_co_idm139879738428544"><h3 class="no_margin">Meenakshi Devidas</h3><p>  <sup>11</sup>Department of Biostatistics, Colleges of Medicine, Public Health &amp; Health Professions, University of Florida, Gainesville, FL</p><div>Find articles by <a href="/pubmed/?term=Devidas%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Meenakshi Devidas</a></div></div><div id="_co_idm139879742708960"><h3 class="no_margin">Jun J. Yang</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Yang%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Jun J. Yang</a></div></div><div id="_co_idm139879746583376"><h3 class="no_margin">Charles G. Mullighan</h3><p>  <sup>4</sup>Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Mullighan%20CG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Charles G. Mullighan</a></div></div><div id="_co_idm139879742065600"><h3 class="no_margin">Jinghui Zhang</h3><p>  <sup>12</sup>Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Zhang%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Jinghui Zhang</a></div></div><div id="_co_idm139879738050208"><h3 class="no_margin">William E. Evans</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Evans%20WE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">William E. Evans</a></div></div><div id="_co_idm139879736989232"><h3 class="no_margin">Sima Jeha</h3><p>  <sup>3</sup>Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Jeha%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Sima Jeha</a></div></div><div id="_co_idm139879733512320"><h3 class="no_margin">Ching-Hon Pui</h3><p>  <sup>3</sup>Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Pui%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Ching-Hon Pui</a></div></div><div id="_co_idm139879744317312"><h3 class="no_margin">Mary V. Relling</h3><p>  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</p><div>Find articles by <a href="/pubmed/?term=Relling%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=28090653">Mary V. Relling</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139879738403232_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139879738403232_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139879738403232_ai" style="display:none"><div class="fm-affl" id="A1" lang="en">  <sup>1</sup>Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN</div><div class="fm-affl" id="A2" lang="en">  <sup>2</sup>Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN</div><div class="fm-affl" id="A3" lang="en">  <sup>3</sup>Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN</div><div class="fm-affl" id="A4" lang="en">  <sup>4</sup>Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN</div><div class="fm-affl" id="A5" lang="en">  <sup>5</sup>Maine Children’s Cancer Program, Scarborough, ME</div><div class="fm-affl" id="A6" lang="en">  <sup>6</sup>Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX</div><div class="fm-affl" id="A7" lang="en">  <sup>7</sup>Department of Pediatrics, New York University Langone Medical Center, New York, NY</div><div class="fm-affl" id="A8" lang="en">  <sup>8</sup>Department of Pediatrics, University of California School of Medicine, San Francisco, CA</div><div class="fm-affl" id="A9" lang="en">  <sup>9</sup>Department of Pediatrics, University of Utah, Salt Lake City, UT</div><div class="fm-affl" id="A10" lang="en">  <sup>10</sup>Department of Pediatrics and the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</div><div class="fm-affl" id="A11" lang="en">  <sup>11</sup>Department of Biostatistics, Colleges of Medicine, Public Health &amp; Health Professions, University of Florida, Gainesville, FL</div><div class="fm-affl" id="A12" lang="en">  <sup>12</sup>Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN</div><div id="FN1">Correspondence: Mary V. Relling, Pharm.D., Chair, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-2794, USA, Phone: 901-595-2348, Fax: 901-595-8869, <a href="mailto:dev@null" data-email="gro.edujts@gniller.yram" class="oemail">gro.edujts@gniller.yram</a></div><div id="FN2"><sup>*</sup>These authors contributed equally to this work.</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm139879738403232_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=28090653" target="pmc_ext" ref="reftype=publisher&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Clin Pharmacol Ther</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC5511775/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="17" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS1.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS1.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS1.docx</a><span style="color:gray"> (13K)</span></div><div class="small guid">GUID:&nbsp;8832F9AE-A232-4B5B-8082-F36948705E57</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS10.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS10.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS10.tif</a><span style="color:gray"> (81K)</span></div><div class="small guid">GUID:&nbsp;085C968B-B9D6-41A8-AB9F-7BB4213CB2EE</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS11.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS11.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS11.tif</a><span style="color:gray"> (137K)</span></div><div class="small guid">GUID:&nbsp;BE7C8B6A-EE66-42DC-BD7E-C5E44FBE2DF1</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS12.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS12.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS12.tif</a><span style="color:gray"> (73K)</span></div><div class="small guid">GUID:&nbsp;29AB959E-5801-4068-A5D5-9F534D4A1122</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS13.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS13.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS13.tif</a><span style="color:gray"> (75K)</span></div><div class="small guid">GUID:&nbsp;E84BB019-8111-4C64-B6E1-F68FDD36891C</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS14.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS14.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS14.tif</a><span style="color:gray"> (405K)</span></div><div class="small guid">GUID:&nbsp;BCF42B75-E83B-41EF-8173-31AC0104E4FD</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS15.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS15.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS15.tif</a><span style="color:gray"> (95K)</span></div><div class="small guid">GUID:&nbsp;39AE64FA-403C-4301-827C-BAAF59F6663B</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS16.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS16.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS16.tif</a><span style="color:gray"> (135K)</span></div><div class="small guid">GUID:&nbsp;F6A9EE73-3744-48F7-8599-B2EFF3E60FD7</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS2.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS2.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS2.docx</a><span style="color:gray"> (16K)</span></div><div class="small guid">GUID:&nbsp;F05BE8D3-69AA-4DC7-9E7B-E2F2C7EBF422</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS3.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS3.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS3.docx</a><span style="color:gray"> (16K)</span></div><div class="small guid">GUID:&nbsp;3C460AE0-D452-4930-96C3-15DBE21A143D</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS4.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS4.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS4.docx</a><span style="color:gray"> (16K)</span></div><div class="small guid">GUID:&nbsp;801D226C-84ED-4A59-8177-7A4D266F47A7</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS5.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS5.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS5.docx</a><span style="color:gray"> (16K)</span></div><div class="small guid">GUID:&nbsp;9E9DA356-48AD-4C47-84E4-04324D9BD101</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS6.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS6.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS6.docx</a><span style="color:gray"> (13K)</span></div><div class="small guid">GUID:&nbsp;AD041547-77FD-4AAD-8B9D-3C6C7C00391F</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS7.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS7.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS7.docx</a><span style="color:gray"> (13K)</span></div><div class="small guid">GUID:&nbsp;DE81A8B2-D05D-41CA-8389-3615FDF49C8C</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS8.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS8.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS8.tif</a><span style="color:gray"> (154K)</span></div><div class="small guid">GUID:&nbsp;52CACB1A-B089-491C-971D-A8113DFBB286</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supp TableS9.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS9.tif" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Supp_TableS9.tif</a><span style="color:gray"> (208K)</span></div><div class="small guid">GUID:&nbsp;D7B88474-9614-47CF-9627-7222950EE13F</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Suppinfo.</strong></div><div><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Suppinfo.docx" data-ga-action="click_feat_suppl">NIHMS843060-supplement-Suppinfo.docx</a><span style="color:gray"> (36K)</span></div><div class="small guid">GUID:&nbsp;F5234DCE-AAAD-4A5E-BD17-38C94E1E9385</div></div></dd></dl></div><div id="idm139879747244656" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139879747244656title">Abstract</h2><!--article-meta--><div><p id="P1" class="p p-first-last">Remission induction therapy for acute lymphoblastic leukemia (ALL) includes medications that may cause hepatotoxicity, including asparaginase. We used a genome-wide association study (GWAS) to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St. Jude Children’s Research Hospital (SJCRH) protocols. Germline DNA was genotyped using arrays and exome sequencing. Adjusting for age, body mass index, ancestry, asparaginase preparation and dosage, the <em>PNPLA3</em> rs738409 (C&gt;G) I148M variant, previously associated with fatty liver disease risk, had the strongest genetic association with ALT (<em>P</em> = 2.5×10<sup>−8</sup>). The <em>PNPLA3</em> rs738409 variant explained 3.8% of the variability in ALT, and partly explained race-related differences in ALT. The <em>PNPLA3</em> rs738409 association was replicated in an independent cohort of 2,285 patients treated on Children’s Oncology Group protocol AALL0232 (<em>P</em> = 0.024). This is an example of a pharmacogenetic variant overlapping with a disease risk variant.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Acute Lymphoblastic Leukemia, Asparaginase, Alanine Aminotransferase, Hepatotoxicity, Pharmacogenomics</span></div></div><div id="S1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S1title">Introduction</h2><p id="P2" class="p p-first">Although cure rates for childhood acute lymphoblastic leukemia (ALL) are approaching 90%,(<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796432">1</a>) therapy is complicated by drug toxicity. Patients who tolerate less treatment due to adverse drug effects may be at a higher risk of relapse.(<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796461">2</a>, <a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796464">3</a>) Hepatotoxicity is a frequent complication leading to treatment interruptions,(<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796438">4</a>–<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796451">6</a>) and several drugs used in ALL therapy are associated with the development of hepatotoxicity, including asparaginase, mercaptopurine, thioguanine, methotrexate, etoposide, and glucocorticoid.(<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796466">7</a>)</p><p id="P3">Some treatment regimens for adults with ALL avoid using and/or dose modify asparaginase and high-dose methotrexate in order to minimize treatment-related hepatotoxicity,(<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796457">8</a>, <a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796453">9</a>) which may contribute to the lower cure rates for adults with ALL. Therefore, studies that can elucidate the mechanism of drug-induced hepatotoxicity during the treatment of ALL may lead to therapeutic strategies that can reduce the frequency of hepatotoxicity, identify patients who are most likely to benefit from treatment, and possibly improve cure rates by reducing treatment interruptions due to hepatotoxicity.</p><p id="P4" class="p p-last">We investigated coding and non-coding genetic variants associated with the elevation of alanine aminotransferase (ALT) after remission induction therapy. A total of 715 St. Jude Children’s Research Hospital patients were evaluable with genotyping and post-induction chemotherapy ALT levels. We tested for replication in 2,285 patients treated on the Children’s Oncology (COG) AALL0232 trial.</p></div><div id="S2" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S2title">Results</h2><p id="P5" class="p p-first">Patients enrolled on St. Jude Children’s Research Hospital (SJCRH) Total XV or Total XVI received similar induction therapy with a few notable differences (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The Total XV protocol included native <em>E. coli</em> asparaginase (Elspar), whereas the Total XVI protocol used PEGylated <em>E. coli</em> asparaginase (Oncaspar). Patients enrolled on Total XV received mercaptopurine, whereas most on Total XVI received thioguanine; those on Total XV received pre-induction window therapy with methotrexate, whereas those on Total XVI did not (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). In both protocols, patients with higher minimal residual disease (MRD) at day 15–19 of induction received additional asparaginase compared to those without.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p10">Chemotherapeutic agents used during Total XV and Total XVI remission induction therapy.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879738852512" class="xtable"><table frame="hsides" rules="rows" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="center">Agents</th><th rowspan="1" colspan="1" valign="middle" align="center">Dosage and Routes and days of induction therapy</th><th rowspan="1" colspan="1" valign="middle" align="center">Number of doses</th><th rowspan="1" colspan="1" valign="middle" align="center">Differences between Total XV and Total XVI</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="center">Prednisone<sup>a</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">40 mg/m<sup>2</sup>/day, PO, T.I.D.; <strong>Total XV</strong>: days 5–32<br><strong>Total XVI:</strong> days 1–28</td><td rowspan="1" colspan="1" valign="middle" align="center">84</td><td rowspan="1" colspan="1" valign="middle" align="center">-</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Vincristine</td><td rowspan="1" colspan="1" valign="middle" align="center">1.5 mg/m<sup>2</sup>/weekly, IV; <strong>Total XV</strong>: days 5, 12, 19, 26<br><strong>Total XVI:</strong> days 1, 8, 15, 22</td><td rowspan="1" colspan="1" valign="middle" align="center">4</td><td rowspan="1" colspan="1" valign="middle" align="center">-</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">MTX<sup>b</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1 g/m<sup>2</sup>, IV, over a 4 or 24 hour infusion</td><td rowspan="1" colspan="1" valign="middle" align="center">1</td><td rowspan="1" colspan="1" valign="middle" align="center">Window MTX was not included on the Total XVI protocol</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Daunorubicin</td><td rowspan="1" colspan="1" valign="middle" align="center">25 mg/m<sup>2</sup>/weekly, IV; <strong>Total XV:</strong> days 5 &amp; 12<br><strong>Total XVI:</strong> days 1 &amp; 8</td><td rowspan="1" colspan="1" valign="middle" align="center">2</td><td rowspan="1" colspan="1" valign="middle" align="center">-</td></tr><tr><td rowspan="2" colspan="1" valign="middle" align="center">ASNase<sup>c</sup></td><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Total XV</strong>: L-ASNase, 10,000 units/m<sup>2</sup>, IM, thrice weekly; days 6, 8, 10, 12, 14, 16</td><td rowspan="1" colspan="1" valign="middle" align="center"><strong>L-ASNase:</strong> 6</td><td rowspan="2" colspan="1" valign="middle" align="center">Preparation, dosage, and route</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Total XVI:</strong> PEG-ASNase, 3,000 units/m<sup>2</sup>, IV; day 3</td><td rowspan="1" colspan="1" valign="middle" align="center"><strong>PEG-ASNase:</strong> 1</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Cyclophosphamide</td><td rowspan="1" colspan="1" valign="middle" align="center">1,000 mg/m<sup>2</sup>, IV; <strong>Total XV</strong>: day 26<br><strong>Total XVI:</strong> day 22</td><td rowspan="1" colspan="1" valign="middle" align="center">1</td><td rowspan="1" colspan="1" valign="middle" align="center">Cyclophosphamide was intensified for standard/high risk patients with ≥ 5% of blast on day 15 of induction for Total XVI patients<sup>d</sup></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Cytarabine</td><td rowspan="1" colspan="1" valign="middle" align="center">75 mg/m<sup>2</sup>/dose, IV; <strong>Total XV</strong>: days 27–30 &amp; 34–37<br><strong>Total XVI</strong>: days 23–26 &amp; 30–33</td><td rowspan="1" colspan="1" valign="middle" align="center">8</td><td rowspan="1" colspan="1" valign="middle" align="center">-</td></tr><tr><td rowspan="2" colspan="1" valign="middle" align="center">Thiopurine</td><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Total XV</strong>: mercaptopurine, 60 mg/m<sup>2</sup>/day, PO; days 26–39</td><td rowspan="2" colspan="1" valign="middle" align="center">14</td><td rowspan="2" colspan="1" valign="middle" align="center">Total XVI received thioguanine; Total XV received mercaptopurine</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Total XVI:</strong> thioguanine<sup>e</sup>, 60 mg/m<sup>2</sup>/day, PO; days 22–35</td></tr></tbody></table></div><div id="largeobj_idm139879738852512" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>a</sup>Oral prednisone was substituted with methylprednisolone at 20 mg/m<sup>2</sup>/day, IV for patients that could not tolerate oral administration.</div><div id="TFN2"><sup>b</sup>Total XV patients were randomized to receive short (4 hour) or prolonged (24 hour) methotrexate infusion.</div><div id="TFN3"><sup>c</sup>Additional 3 doses of L-ASNase were given if day 19 MRD ≥ 5% on days 19, 21, 23 to Total XV patients. Additional PEG-ASNase dose was given if day 15 MRD ≥ 1% on day 15 to Total XVI patients.</div><div id="TFN4"><sup>d</sup>Total XVI patients with day 15 MRD ≥ 5% received cyclophosphamide at 300 mg/m2, IV, q12 hours for 4 doses on days 22–23.</div><div id="TFN5"><sup>e</sup>TPMT heterozygote or TPMT deficient Total XVI patients received mercaptopurine at 60 mg/m<sup>2</sup>/dose, PO instead of thioguanine.</div><div id="TFN6"><p id="__p16" class="p p-first-last">Abbreviations: PO, by mouth; IV, intravenous; IM, intramuscular; T.I.D., three times a day; MRD, minimal residual disease; MTX, methotrexate; ASNase, asparaginase</p></div></div></div><p id="P6">Overall, 715 patients were evaluable for post-induction ALT data in the discovery cohort (<a href="/pmc/articles/PMC5511775/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S1</a>). By univariate analysis (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S1</a>), treatment protocol (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>), additional asparaginase during induction (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>), race group (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1C</span></a>), age (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1D</span></a>), body mass index (BMI) percentile (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1E</span></a>), and gender were associated with post-induction ALT levels. In multivariate analysis (<a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>), higher ALT levels were associated with Total XVI treatment protocol (<em>P</em> = 0.041), receiving additional induction asparaginase (<em>P</em> = 2.7×10<sup>−4</sup>), non-black race (<em>P</em> = 8.7×10<sup>−13</sup> for whites and <em>P</em> = 2.6×10<sup>−7</sup> for Hispanics), older age (<em>P</em> = 1.4×10<sup>−6</sup>), and higher BMI (<em>P</em> = 2.9×10<sup>−3</sup>). Race group accounted for 7.2% of the variability in ALT levels (<a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Focusing on the National Cancer Institute’s common toxicity criteria (CTCAE) categories of ALT toxicity, Total XVI patients had more grade 2–3 ALT elevations compared to Total XV patients (<em>P</em> = 5.8×10<sup>−3</sup>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S2A</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879736742480" class="figure"><a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5511775_nihms843060f1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms843060f1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5511775/bin/nihms843060f1.jpg"></a></div><div id="largeobj_idm139879736742480" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC5511775/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>ALT level variation in pediatric ALL patients</strong><p id="__p7">(A) Total XVI patients receiving PEGylated <em>E. coli</em> asparaginase had higher ALT levels compared to Total XV patients receiving native <em>E. coli</em> asparaginase (<em>P</em> = 3.0×10<sup>−3</sup>). (B) Among Total XV and Total XVI patients, those receiving additional doses of asparaginase during induction due to a higher ALL burden at day 15–19 had higher ALT levels compared to patients receiving fewer doses of asparaginase (<em>P</em> = 3.5×10<sup>−6</sup>). (C) Among Total XV and Total XVI patients, whites (<em>P</em> = 3.3×10<sup>−10</sup>) and Hispanics (<em>P</em> = 3.3×10<sup>−7</sup>) had higher ALT levels compared to blacks. (D) ALT levels were correlated with age (yrs) in the SJCRH discovery cohort (N = 715, r = 0.20, <em>P</em> = 9.4×10<sup>−8</sup>). (E) ALT levels were positively correlated with BMI percentile in the SJCRH discovery cohort (N = 715, r = 0.11, <em>P</em> = 5.2×10<sup>−3</sup>). The P values indicated are from univariate analyses (<a href="#SD1" rid="SD1" class=" supplementary-material">Table S1</a>).</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p17">Demographics of ALL patients with serum ALT measurement data.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879736049328" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="3" colspan="1" valign="middle" align="right">Characteristics</th><th colspan="3" rowspan="1" valign="middle" align="center">Treatment protocol</th></tr><tr><th colspan="3" rowspan="1" valign="bottom" align="center">
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="center">SJCRH (Total XV)</th><th rowspan="1" colspan="1" valign="middle" align="center">SJRCH (Total XVI)</th><th rowspan="1" colspan="1" valign="middle" align="center">COG AALL0232<sup>d</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Sample Size</strong> (n)</td><td rowspan="1" colspan="1" valign="top" align="center">373</td><td rowspan="1" colspan="1" valign="top" align="center">342</td><td rowspan="1" colspan="1" valign="top" align="center">2285</td></tr><tr><td colspan="4" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Age</strong> (n ≥ 10, mean in years)</td><td rowspan="1" colspan="1" valign="top" align="center">102 (27.4%),<sup>a</sup><br>7.1</td><td rowspan="1" colspan="1" valign="top" align="center">92 (26.9%),<sup>a</sup><br>7.2</td><td rowspan="1" colspan="1" valign="top" align="center">1,468 (64.3%),<sup>a</sup><br>10.6</td></tr><tr><td colspan="4" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Gender</strong> (n male)</td><td rowspan="1" colspan="1" valign="top" align="center">206 (55.2%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">198 (57.9%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">1,244 (54.4%)<sup>a</sup></td></tr><tr><td colspan="4" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Race group</strong><sup>b</sup></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Whites</td><td rowspan="1" colspan="1" valign="top" align="center">261 (70.0%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">227 (66.4%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">1,275 (55.8%)<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Blacks</td><td rowspan="1" colspan="1" valign="top" align="center">64 (17.2%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">47 (13.7%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">139 (6.1%)<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Hispanics</td><td rowspan="1" colspan="1" valign="top" align="center">24 (6.4%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">36 (10.5%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">601 (26.3%)<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Others</td><td rowspan="1" colspan="1" valign="top" align="center">24 (6.4%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">32 (9.4%)<sup>a</sup></td><td rowspan="1" colspan="1" valign="top" align="center">270 (11.8%)<sup>a</sup></td></tr><tr><td colspan="4" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Diagnostic ALT(IU/L)</strong><sup>c</sup></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Median (range)</td><td rowspan="1" colspan="1" valign="top" align="center">21 (3 – 3866)</td><td rowspan="1" colspan="1" valign="top" align="center">20 (4 – 2442)</td><td rowspan="1" colspan="1" valign="top" align="center">NA</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">95% confidence interval</td><td rowspan="1" colspan="1" valign="top" align="center">22.9 – 27.9</td><td rowspan="1" colspan="1" valign="top" align="center">22.4 – 27.9</td><td rowspan="1" colspan="1" valign="top" align="center">NA</td></tr><tr><td colspan="4" rowspan="1" valign="bottom" align="left">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right"><strong>Post-induction ALT(IU/L)</strong></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">Median (range)</td><td rowspan="1" colspan="1" valign="top" align="center">38 (4 – 416)</td><td rowspan="1" colspan="1" valign="top" align="center">44 (7 – 321)</td><td rowspan="1" colspan="1" valign="top" align="center">NA</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="right">95% confidence interval</td><td rowspan="1" colspan="1" valign="top" align="center">35.5 – 40.9</td><td rowspan="1" colspan="1" valign="top" align="center">41.3 – 48.4</td><td rowspan="1" colspan="1" valign="top" align="center">NA</td></tr></tbody></table></div><div id="largeobj_idm139879736049328" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN7"><sup>a</sup>The percentage of patients with the characteristic described in the first column.</div><div id="TFN8"><sup>b</sup>Whites were defined as having &gt; 90% Northern European ancestry (CEU), blacks as having &gt; 70% West African ancestry (YRI), Hispanics as having Native American ancestry &gt; 10% and greater than their African ancestry percentage, and others as those whose ancestry was outside the above boundaries.</div><div id="TFN9"><sup>c</sup>Diagnostic ALT (pre-induction therapy) was evaluable in 337 of 373 Total XV patients and 321 of 342 Total XVI patients, and ALT levels were lower at diagnosis than at end-of-induction (<em>P</em> &lt; 2.2×10<sup>−16</sup>, paired t-test for 658 patients evaluable at both times, see also <a href="#SD17" rid="SD17" class=" supplementary-material">Figures S8&amp;S9</a>).</div><div id="TFN10"><sup>d</sup>No discrete ALT levels were available for COG AALL0232 patients.</div><div id="TFN11"><p id="__p22" class="p p-first-last">NA, not available</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p23">Multivariate analyses of covariates associated with alanine transaminase levels during Total XV and Total XVI remission induction therapy.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879739047760" class="xtable"><table frame="hsides" rules="none" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="center"></th><th colspan="3" rowspan="1" valign="middle" align="center">Without inclusion of <em>PNPLA3</em> rs738409</th><th colspan="3" rowspan="1" valign="middle" align="center">Including <em>PNPLA3</em> rs738409</th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="center"></th><th colspan="3" rowspan="1" valign="bottom" align="center">
<hr></th><th colspan="3" rowspan="1" valign="bottom" align="center">
<hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="center">Covariate</th><th rowspan="1" colspan="1" valign="middle" align="center">Effect size<sup>a</sup></th><th rowspan="1" colspan="1" valign="middle" align="center">P value</th><th rowspan="1" colspan="1" valign="middle" align="center">% of ALT level variability explained</th><th rowspan="1" colspan="1" valign="middle" align="center">Effect size<sup>a</sup></th><th rowspan="1" colspan="1" valign="middle" align="center">P value</th><th rowspan="1" colspan="1" valign="middle" align="center">% of ALT level variability explained</th></tr><tr><th rowspan="1" colspan="1" valign="bottom" align="center">
<hr></th><th colspan="3" rowspan="1" valign="bottom" align="center">
<hr></th><th colspan="3" rowspan="1" valign="bottom" align="center">
<hr></th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Induction ASNase:</strong> Additional vs. standard schedule</td><td rowspan="1" colspan="1" valign="middle" align="center">1.26 (1.11–1.42)</td><td rowspan="1" colspan="1" valign="middle" align="center">2.7×10<sup>−4</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.7%</td><td rowspan="1" colspan="1" valign="middle" align="center">1.27 (1.12–1.43)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.1×10<sup>−4</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.8%</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Gender:</strong> Male vs. female</td><td rowspan="1" colspan="1" valign="middle" align="center">1.08 (0.97–1.20)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.16</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Age:</strong> Continuous variable</td><td rowspan="1" colspan="1" valign="middle" align="center">1.03 (1.02–1.04)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.4×10<sup>−6</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">2.9%</td><td rowspan="1" colspan="1" valign="middle" align="center">1.03 (1.02–1.04)</td><td rowspan="1" colspan="1" valign="middle" align="center">8.6×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">3.4%</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Race group</strong><sup>b</sup>:</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Whites vs. blacks</td><td rowspan="1" colspan="1" valign="middle" align="center">1.70 (1.48–1.96)</td><td rowspan="1" colspan="1" valign="middle" align="center">8.7×10<sup>−13</sup></td><td rowspan="3" colspan="1" valign="middle" align="center">7.2%</td><td rowspan="1" colspan="1" valign="middle" align="center">1.62 (1.41–1.87)</td><td rowspan="1" colspan="1" valign="middle" align="center">3.7×10<sup>−11</sup></td><td rowspan="3" colspan="1" valign="middle" align="center">5.3%</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Hispanic vs. blacks</td><td rowspan="1" colspan="1" valign="middle" align="center">1.77 (1.43–2.20)</td><td rowspan="1" colspan="1" valign="middle" align="center">2.6×10<sup>−7</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.57 (1.26–1.95)</td><td rowspan="1" colspan="1" valign="middle" align="center">6.6×10<sup>−5</sup></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">Others vs. blacks</td><td rowspan="1" colspan="1" valign="middle" align="center">1.52 (1.21–1.90)</td><td rowspan="1" colspan="1" valign="middle" align="center">3.2×10<sup>−4</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.41 (1.14–1.76)</td><td rowspan="1" colspan="1" valign="middle" align="center">2.0×10<sup>−3</sup></td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>Protocol:</strong> Total XVI vs. Total XV</td><td rowspan="1" colspan="1" valign="middle" align="center">1.11 (1.00–1.24)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.041</td><td rowspan="1" colspan="1" valign="middle" align="center">0.49%</td><td rowspan="1" colspan="1" valign="middle" align="center">1.12 (1.01–1.24)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.025</td><td rowspan="1" colspan="1" valign="middle" align="center">0.58%</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong>BMI percentile:</strong> Continuous variable</td><td rowspan="1" colspan="1" valign="middle" align="center">1.29 (1.09–1.52)</td><td rowspan="1" colspan="1" valign="middle" align="center">2.9×10<sup>−3</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.3%</td><td rowspan="1" colspan="1" valign="middle" align="center">1.28 (1.09–1.50)</td><td rowspan="1" colspan="1" valign="middle" align="center">2.7×10<sup>−3</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">1.0%</td></tr><tr><td rowspan="1" colspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td><td colspan="3" rowspan="1" valign="bottom" align="center">
<hr></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center"><strong><em>PNPLA3</em> rs738409 genotype:</strong> Numeric variable<sup>c</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">NA</td><td rowspan="1" colspan="1" valign="middle" align="center">1.29 (1.18–1.40)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.2×10<sup>−8</sup></td><td rowspan="1" colspan="1" valign="middle" align="center">3.8%</td></tr></tbody></table></div><div id="largeobj_idm139879739047760" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN12"><sup>a</sup>The effect size refers to the exponent of the beta coefficient estimated from the linear regression. Numbers in parentheses indicate 95% confidence interval.</div><div id="TFN13"><sup>b</sup>Whites were defined as having &gt; 90% Northern European ancestry, blacks as having &gt; 70% West African ancestry, Hispanics as having Native American ancestry greater than 10% and Native American ancestry was greater than their percent African ancestry, and others were those whose ancestry was outside the above boundaries.</div><div id="TFN14"><sup>c</sup>Genotype of SNP was treated as numeric variable, which equals to the number of minor allele in the genotype of each patient.</div><div id="TFN15"><p id="__p27" class="p p-first-last">NA, not applicable</p></div></div></div><p id="P7">To identify genetic variants associated with post-induction ALT levels in the SJCRH discovery cohort, we used a multivariate linear regression model including treatment protocol, use of additional asparaginase doses, percentage of Northern European ancestry, West African ancestry and Native American ancestry, age, and BMI percentile as covariates along with genotypes. The strongest association (<em>P</em> = 2.5×10<sup>−8</sup>) with ALT levels was with the <em>PNPLA3</em> rs738409 (C&gt;G) I148M variant (<a href="/pmc/articles/PMC5511775/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2A</span></a>, <a href="/pmc/articles/PMC5511775/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>), a missense polymorphism known as a quantitative trait locus (QTL) for ALT in the general population.(<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796423">10</a>) The median ALT level for patients of CC, GC, and GG diplotypes was 35, 45, and 58 IU/L, respectively. When ALT was translated into CTCAE categories of ALT toxicity, the frequency of higher ALT grade (grade &gt; 2) was 2.6%, 3.9% and 5.3% respectively among patients of CC, GC, and GG diplotypes (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S2B</a>). The association of <em>PNPLA3</em> rs738409 with ALT treated as a continuous variable was observed in both Total XV (<em>P</em> = 5.5×10<sup>−6</sup>) and Total XVI (<em>P</em> = 2.7×10<sup>−4</sup>) (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S3A</a>), and differed within race groups (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3A</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S3B</a>). Interestingly, the minor allele frequency (MAF) of <em>PNPLA3</em> rs738409 was highest among Hispanics (44.2%), followed by whites (23.1%), and lowest in blacks (13.1%) in our cohort, as observed in previous studies,(<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796459">11</a>) and followed the same trend as their post-induction ALT levels (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3B</span></a>). Principal component analysis (PCA) within each race group did not uncover any stratification among the patients carrying the different <em>PNPLA3</em> rs738409 genotypes (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S4A–C</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC5511775/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879735386112" class="figure"><a href="/pmc/articles/PMC5511775/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=5511775_nihms843060f2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms843060f2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC5511775/bin/nihms843060f2.jpg"></a></div><div id="largeobj_idm139879735386112" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC5511775/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Manhattan plots of inverse P values for genome-wide SNP associations with ALT levels</strong><p id="__p8">(A) Association between SNPs and natural logarithm ALT levels versus each chromosome for Total XV and XVI patients (N = 715). The analysis identified a variant in <em>PNPLA3 (</em>rs738409) associated with ALT levels. (B) Association between SNPs and ALT levels versus each chromosome for black patients in Total XV and XVI patients (n = 111). A variant near <em>PIGV</em> and a variant in 3′-UTR of <em>GREB1</em> were associated with ALT levels with genome-wide significance.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879736822880" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.
Object name is nihms843060f3.jpg" title="An external file that holds a picture, illustration, etc.
Object name is nihms843060f3.jpg" src="/pmc/articles/PMC5511775/bin/nihms843060f3.jpg"></div></a><div id="largeobj_idm139879736822880" class="largeobj-link align_right" style="display: none"><a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"></a><a target="object" href="/pmc/articles/PMC5511775/figure/F3/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC5511775/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Post-induction ALT levels varied by genotype in 715 SJCRH Total XV and XVI patients</strong><p id="__p9">(A) Boxplots of ALT levels by <em>PNPLA3</em> rs738409 genotype in blacks (n = 111, <em>P</em> = 0.20), whites (n = 488, <em>P</em> = 1.5×10<sup>−6</sup>), and Hispanics (n = 60, <em>P</em> = 0.058) from the SJCRH discovery cohort. (B) Boxplots of ALT levels by <em>PNPLA3</em> rs738409 MAF in blacks, whites and Hispanics from the SJCRH discovery cohort. (P values of whites and Hispanics vs. blacks are 3.3×10<sup>−10</sup> and 3.3×10<sup>−7</sup> respectively in univariate analysis.) (C) Boxplots of ALT levels by <em>PIGV</em> rs12748152 genotype in blacks (n = 102, <em>P</em> = 1.3×10<sup>−8</sup>), whites (n = 471, <em>P</em> = 0.14), and Hispanics (n = 60, <em>P</em> = 0.59) from the SJCRH discovery cohort. (D) Boxplots of ALT levels by <em>GREB1</em> rs149940960 genotype in blacks (n = 86, <em>P</em> = 2.0×10<sup>−8</sup>) from the SJCRH discovery cohort. The boxes depict median with upper and lower quartiles.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p id="__p28">Top 20 variants associated with post-induction ALT in the combined SJCRH Total XV and Total XVI cohort.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139879739934656" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left">rsID</th><th rowspan="1" colspan="1" valign="middle" align="left">Hg19 position</th><th rowspan="1" colspan="1" valign="middle" align="left">Major allele<sup>a</sup></th><th rowspan="1" colspan="1" valign="middle" align="left">Minor allele<sup>a</sup></th><th rowspan="1" colspan="1" valign="middle" align="left">Platform</th><th rowspan="1" colspan="1" valign="middle" align="left">P value</th><th rowspan="1" colspan="1" valign="middle" align="left">Effect size<sup>b</sup></th><th rowspan="1" colspan="1" valign="middle" align="left">Confidence interval</th><th rowspan="1" colspan="1" valign="middle" align="left">Gene</th><th rowspan="1" colspan="1" valign="middle" align="left">Function annotation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs738409</td><td rowspan="1" colspan="1" valign="top" align="left">22:44324727</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">exomechip</td><td rowspan="1" colspan="1" valign="top" align="left">2.52E-08</td><td rowspan="1" colspan="1" valign="top" align="left">1.29</td><td rowspan="1" colspan="1" valign="top" align="left">1.04–1.58</td><td rowspan="1" colspan="1" valign="top" align="left">PNPLA3</td><td rowspan="1" colspan="1" valign="top" align="left">missense</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs144104656</td><td rowspan="1" colspan="1" valign="top" align="left">2:119418867</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">1.60E-07</td><td rowspan="1" colspan="1" valign="top" align="left">8.04</td><td rowspan="1" colspan="1" valign="top" align="left">1.36–47.52</td><td rowspan="1" colspan="1" valign="top" align="left">EN1</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2294915</td><td rowspan="1" colspan="1" valign="top" align="left">22:44340904</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">5.72E-07</td><td rowspan="1" colspan="1" valign="top" align="left">1.26</td><td rowspan="1" colspan="1" valign="top" align="left">1.03–1.53</td><td rowspan="1" colspan="1" valign="top" align="left">PNPLA3</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs147481775</td><td rowspan="1" colspan="1" valign="top" align="left">22:32225363</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">5.77E-07</td><td rowspan="1" colspan="1" valign="top" align="left">4.66</td><td rowspan="1" colspan="1" valign="top" align="left">1.22–17.88</td><td rowspan="1" colspan="1" valign="top" align="left">DEPDC5</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs74709575</td><td rowspan="1" colspan="1" valign="top" align="left">13:38615256</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">1.23E-06</td><td rowspan="1" colspan="1" valign="top" align="left">4.52</td><td rowspan="1" colspan="1" valign="top" align="left">1.19–17.19</td><td rowspan="1" colspan="1" valign="top" align="left">TRPC4</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs17857135</td><td rowspan="1" colspan="1" valign="top" align="left">17:78262161</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">exomeseq</td><td rowspan="1" colspan="1" valign="top" align="left">1.68E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.78</td><td rowspan="1" colspan="1" valign="top" align="left">0.63–0.97</td><td rowspan="1" colspan="1" valign="top" align="left">RNF213</td><td rowspan="1" colspan="1" valign="top" align="left">missense</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs112769843</td><td rowspan="1" colspan="1" valign="top" align="left">12:62308665</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">1.76E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.54</td><td rowspan="1" colspan="1" valign="top" align="left">0.32–0.94</td><td rowspan="1" colspan="1" valign="top" align="left">FAM19A2</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs11696756</td><td rowspan="1" colspan="1" valign="top" align="left">20:22982087</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">2.59E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.39</td><td rowspan="1" colspan="1" valign="top" align="left">1.03–1.86</td><td rowspan="1" colspan="1" valign="top" align="left">SSTR4</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs12530134</td><td rowspan="1" colspan="1" valign="top" align="left">6:170919470</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">exomechip</td><td rowspan="1" colspan="1" valign="top" align="left">3.37E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.36</td><td rowspan="1" colspan="1" valign="top" align="left">1.03–1.80</td><td rowspan="1" colspan="1" valign="top" align="left">PDCD2</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs117483095</td><td rowspan="1" colspan="1" valign="top" align="left">9:132784775</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">3.43E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.62</td><td rowspan="1" colspan="1" valign="top" align="left">1.05–2.50</td><td rowspan="1" colspan="1" valign="top" align="left">FNBP1</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs113941845</td><td rowspan="1" colspan="1" valign="top" align="left">2:239501832</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.01E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.24</td><td rowspan="1" colspan="1" valign="top" align="left">1.02–1.51</td><td rowspan="1" colspan="1" valign="top" align="left">ASB1</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs145145722</td><td rowspan="1" colspan="1" valign="top" align="left">7:17243557</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.03E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.42</td><td rowspan="1" colspan="1" valign="top" align="left">0.19–0.92</td><td rowspan="1" colspan="1" valign="top" align="left">AHR</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs11020478</td><td rowspan="1" colspan="1" valign="top" align="left">11:93409448</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.30E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.21</td><td rowspan="1" colspan="1" valign="top" align="left">1.02–1.43</td><td rowspan="1" colspan="1" valign="top" align="left">KIAA1731</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs1348850</td><td rowspan="1" colspan="1" valign="top" align="left">2:178418575</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">exomechip</td><td rowspan="1" colspan="1" valign="top" align="left">4.31E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.22</td><td rowspan="1" colspan="1" valign="top" align="left">1.02–1.46</td><td rowspan="1" colspan="1" valign="top" align="left">TTC30B</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs7024024</td><td rowspan="1" colspan="1" valign="top" align="left">9:92210595</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.37E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.82</td><td rowspan="1" colspan="1" valign="top" align="left">0.68–0.98</td><td rowspan="1" colspan="1" valign="top" align="left">GADD45G</td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs149940960</td><td rowspan="1" colspan="1" valign="top" align="left">2:11781618</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">exomeseq</td><td rowspan="1" colspan="1" valign="top" align="left">4.41E-06</td><td rowspan="1" colspan="1" valign="top" align="left">0.16</td><td rowspan="1" colspan="1" valign="top" align="left">0.03–0.85</td><td rowspan="1" colspan="1" valign="top" align="left">GREB1</td><td rowspan="1" colspan="1" valign="top" align="left">3′-UTR</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs143969105</td><td rowspan="1" colspan="1" valign="top" align="left">12:58201465</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">exomeseq</td><td rowspan="1" colspan="1" valign="top" align="left">4.48E-06</td><td rowspan="1" colspan="1" valign="top" align="left">8.68</td><td rowspan="1" colspan="1" valign="top" align="left">1.21–62.08</td><td rowspan="1" colspan="1" valign="top" align="left">TSFM</td><td rowspan="1" colspan="1" valign="top" align="left">missense</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs75870332</td><td rowspan="1" colspan="1" valign="top" align="left">14:27753539</td><td rowspan="1" colspan="1" valign="top" align="left">T</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.88E-06</td><td rowspan="1" colspan="1" valign="top" align="left">1.51</td><td rowspan="1" colspan="1" valign="top" align="left">1.04–2.19</td><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="left">intergenic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs58800477</td><td rowspan="1" colspan="1" valign="top" align="left">6:20759577</td><td rowspan="1" colspan="1" valign="top" align="left">A</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">imputed</td><td rowspan="1" colspan="1" valign="top" align="left">4.94E-06</td><td rowspan="1" colspan="1" valign="top" align="left">4.10</td><td rowspan="1" colspan="1" valign="top" align="left">1.13–14.91</td><td rowspan="1" colspan="1" valign="top" align="left">CDKAL1</td><td rowspan="1" colspan="1" valign="top" align="left">intronic</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs738409</td><td rowspan="1" colspan="1" valign="top" align="left">22:44324727</td><td rowspan="1" colspan="1" valign="top" align="left">C</td><td rowspan="1" colspan="1" valign="top" align="left">G</td><td rowspan="1" colspan="1" valign="top" align="left">exomechip</td><td rowspan="1" colspan="1" valign="top" align="left">2.52E-08</td><td rowspan="1" colspan="1" valign="top" align="left">1.29</td><td rowspan="1" colspan="1" valign="top" align="left">1.04–1.58</td><td rowspan="1" colspan="1" valign="top" align="left">PNPLA3</td><td rowspan="1" colspan="1" valign="top" align="left">missense</td></tr></tbody></table></div><div id="largeobj_idm139879739934656" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC5511775/table/T4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN16"><sup>a</sup>Alleles were assigned as major or minor ones based on their frequency in the cohort of our study.</div><div id="TFN17"><sup>b</sup>The effect size refers to the exponent of the beta coefficient of the minor allele estimated from the linear regression in PLINK. An effect size greater than 1 indicates the minor allele is the risk allele.</div></div></div><p id="P8">Because the impact of <em>PNPLA3</em> rs738409 on ALT elevation differed by race (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3A</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S3B</a>), and because ALT levels differed among races in the same direction that the <em>PNPLA3</em> rs738409 MAF did (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3B</span></a>), we questioned whether the association between race and ALT elevation was accounted for mostly by this variant. After adding <em>PNPLA3</em> rs738409 genotype to a multivariate analysis for determinants of ALT levels, the <em>PNPLA3</em> SNP accounted for 3.8% of ALT variability, and race group still remained an important risk factor (<em>P</em> = 3.7×10<sup>−11</sup>, 6.6×10<sup>−5</sup> and 2.0×10<sup>−3</sup> for whites, Hispanics and others vs. blacks, respectively), and explained 5.3% of the variability in ALT elevation after incorporating the <em>PNPLA3</em> SNP (<a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Therefore, we performed three separate ancestry-specific GWAS among whites, blacks and Hispanics (<a href="#SD9" rid="SD9" class=" supplementary-material">Tables S2</a>–<a href="#SD11" rid="SD11" class=" supplementary-material">S4</a>) to identify additional possible race-specific genetic determinants of ALT, including the percentage of West African and Native American ancestries as covariates in the GWASs within blacks and Hispanics, respectively. Two variants, <em>PIGV</em> rs12748152 and <em>GREB1</em> rs149940960, had P values approaching genome-wide significance and only in blacks (<em>P</em> = 1.3×10<sup>−8</sup> and 2.0×10<sup>−8</sup> respectively, <a href="/pmc/articles/PMC5511775/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2B</span></a>, <a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>3C&amp;D</span></a>). Coincidentally, the three subjects harboring the minor allele of <em>GREB1</em> rs149940960 also had the minor allele of <em>PIGV</em> rs12748152. Both variants were associated with lower ALT only in blacks (<em>P</em> = 0.14 in whites and <em>P</em> = 0.59 in Hispanics for <em>PIGV</em> rs12748152, <a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3C</span></a>; the <em>GREB1</em> rs149940960 was detected in blacks only). The <em>PIGV</em> rs12748152 had a higher MAF in whites (7.1%) than blacks (1.8%) and Hispanics (0.8%), whereas the <em>GREB1</em> rs149940960 had MAF = 1.7% in blacks, in accordance with the general population frequency (1000 Genomes). In addition, when race structure was calculated with PCA and the first five principal components were used as covariates in each race-specific GWAS, the top SNPs and P values for association with ALT did not change substantially (<a href="#SD7" rid="SD7" class=" supplementary-material">Tables S2</a>–<a href="#SD11" rid="SD11" class=" supplementary-material">S4</a>), and PCA within blacks did not uncover any stratification among the patients carrying the different <em>PIGV</em> rs12748152 genotypes (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S4D</a>). <em>PNPLA3</em> rs6006460 (G&gt;T) was previously reported to protect blacks from the development of nonalcoholic fatty liver disease (NAFLD).(<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796443">12</a>) The <em>PNPLA3</em> rs6006460 minor allele was among the protective variants in our discovery cohort as well (<em>P</em> = 3.2×10<sup>−3</sup>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S5A</a>), and the effect was significant when restricted only to blacks in our cohort (<em>P</em> = 0.041, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S5B</a>). The frequency of this protective variant was highest in the blacks of our cohort (MAF = 11%) and thus may have counteracted the adverse effects of carrying the risk allele of <em>PNPLA3</em> rs738409, therefore helping to explain why <em>PNPLA3</em> rs738409 was not significantly associated with increased ALT among blacks (<em>P</em> = 0.20, <a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figures 3A</span></a>&amp;<a href="#SD17" rid="SD17" class=" supplementary-material">S3B</a>). In blacks, the <em>PNPLA3</em> rs738409 explained 1.3% of the variability in ALT level (<em>P</em> = 0.065) while <em>PNPLA3</em> rs6006460 explained another 5.8% (<em>P</em> = 0.014). In contrast, among non-blacks in the discovery cohort, <em>PNPLA3</em> rs738409 explained 4.2% of the variability whereas <em>PNPLA3</em> rs6006460 added only 1.2% (<em>P</em> &lt; 2.2×10<sup>−16</sup> for both).</p><p id="P9">A total of 109 variants within the <em>PNPLA3</em> gene were found in the SJCRH cohort, 65 of which had nominal P values of &lt; 0.05 for their association with ALT, with 61/65 having the minor allele associated with higher ALT (<a href="#SD12" rid="SD12" class=" supplementary-material">Table S5</a>). A gene-level GWAS including the same covariates as the single SNP GWAS (protocol, asparaginase dosage, percent ancestry, age, and BMI percentile) identified <em>PNPLA3</em> as an overall detrimental gene for ALT levels (<em>P</em> = 0.0093), reflecting the collective impact of <em>PNPLA3</em> variants.</p><p id="P10">In the replication cohort AALL0232, ALT elevation was classified into grade &gt; 2 vs. grade ≤ 2. Accounting for the significant covariates of age, race, gender, and the induction steroid (<a href="#SD13" rid="SD13" class=" supplementary-material">Table S6</a>), <em>PNPLA3</em> rs738409 was associated with the frequency of grade &gt; 2 ALT elevations in the entire AALL0232 cohort (<em>P</em> = 0.024) (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S6</a>) and when the analysis was limited to Hispanics (<em>P</em> = 0.01), thus independently replicating the polymorphism’s association.</p><p id="P11" class="p p-last">Because the <em>PNPLA3</em> variant rs738409 has been previously linked to elevated ALT levels and to the development of hepatic steatosis in the general population,(<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796431">13</a>) its association with elevated ALT after remission induction therapy suggested that asparaginase may influence blood ALT levels through dysregulation of hepatic lipids. We confirmed that PEGylated <em>E. coli</em> asparaginase caused hepatic steatosis in mice, as evidenced by a doubling in Oil-red O (ORO) staining in livers of mice treated with the drug compared to control (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S7</a>).</p></div><div id="S3" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S3title">Discussion</h2><p id="P12" class="p p-first">Patients with ALL are at increased risk for the development of toxicities, including hepatotoxicity, which is partly reflected by elevated serum aminotransferase levels.(<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796421">3</a>) Our objectives were to use a genome-wide approach to determine inherited variation associated with ALT elevation among a racially diverse set of pediatric patients with ALL at a uniform time point (the end of remission induction), adjusting for clinical and other covariates potentially associated with increased ALT levels. Although many ALL medications can contribute to elevations in serum ALT, our multivariate analysis suggested that elevated post-induction chemotherapy ALT levels were linked to asparaginase exposure (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figures 1A&amp;B</span></a>, <a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Patients on Total XVI (who all received PEGylated <em>E. coli</em> asparaginase) had higher ALT levels compared to the Total XV patients (who all received the less potent native <em>E. coli</em> asparaginase) (<em>P</em> = 0.041, <a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>, <a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>), despite the fact that patients on Total XV received pre-induction high-dose methotrexate whereas those on Total XVI did not (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>), suggesting an effect of asparaginase preparation on hepatotoxicity. Moreover, those who received additional asparaginase during induction had higher ALT levels compared to those that did not receive additional asparaginase (<em>P</em> = 2.7×10<sup>−4</sup>, <a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>, <a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Interestingly, serum bilirubin at end of induction did not differ by asparaginase exposure (data not shown). Adjusting for treatment, host-related covariates (e.g., age, BMI percentile) and ancestry, we found that the <em>PNPLA3</em> rs738409 I148M variant associated with higher ALT levels. This is the identical genetic variant that has previously been linked to ALT elevation in the general population,(<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796430">10</a>) non-alcoholic fatty liver disease (NAFLD),(<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796441">12</a>, <a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796436">14</a>, <a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796426">15</a>) NAFLD severity,(<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796442">16</a>) and hepatic fibrosis(<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796448">15</a>) in genome-wide studies. The effect on NAFLD susceptibility and severity was confirmed by meta-analyses.(<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796446">17</a>) This variant was also associated with poor chronic hepatitis C treatment response,(<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796445">18</a>) hepatocellular carcinoma,(<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796455">19</a>) and insulin resistance.(<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796439">20</a>) Overall in the discovery cohort of 715 patients, the median increase in ALT was 12 IU/L, or 33.3% of the median of the major allele homozygous (C/C) group, for each minor allele of <em>PNPLA3</em> (<em>P</em> = 0.032), compared to a 6.0% increase for each allele observed in the general population,(<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796429">10</a>) suggesting that the effect of the variant is amplified during ALL therapy, and consistent with larger effect sizes for pharmacogenetic traits.(<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_725128231">21</a>)</p><p id="P13">Because of hepatic infiltration of ALL at diagnosis and the prolonged use of potentially hepatotoxic chemotherapy, there is no optimal time to measure “baseline” ALT in ALL.(<a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796435">22</a>) We did examine ALT levels at diagnosis within the SJCRH cohort and showed that serum ALT levels were lower at diagnosis than at end-of-induction (<em>P</em> &lt; 2.2×10<sup>−16</sup>, paired t-test, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S8</a>, <a href="/pmc/articles/PMC5511775/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>), and that <em>PNPLA3</em> rs738409 remains a significant risk factor (<em>P</em> = 4.4×10<sup>−6</sup>) for post-induction ALT elevation even after including diagnostic ALT as a covariate.</p><p id="P14">Patatin-like Phospholipase Domain Containing Protein 3 (PNPLA3 or adiponutrin) is a member of the family of patatin-like lipolytic enzymes involved in triacylglycerol metabolism and signaling.(<a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796458">23</a>) It has been shown that substituting methionine for isoleucine at position 148 markedly compromised the catalytic velocity of PNPLA3.(<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796440">24</a>) This is reflected in knock-in mice studies suggesting that the <em>PNPLA3</em> I148M variant leads to an increased risk of hepatotoxicity due to accumulation of PNPLA3 on lipid droplets in the liver, a reduction in triglyceride hydrolase activity, and accumulation of hepatic triglycerides.(<a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796449">25</a>) Our finding that the top ranked genetic variation associated with drug-induced liver dysfunction after ALL therapy is identical to one of the top genetic risk factors for constitutive liver dysfunction is remarkable, and has implications for the field of pharmacogenetics and its use to predict drug toxicities.</p><p id="P15">We confirmed that asparaginase exposure in mice indeed led to an accumulation of hepatic lipids and neutral triglycerides (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S7</a>). The results suggest that the mechanism of asparaginase-induced hepatotoxicity may be similar to that of hepatic steatosis, and may be attenuated by therapies that can mitigate hepatic triglyceride accumulation. These results may have particular implications for adults with ALL, in whom hepatotoxicity is common.(<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_725128232">26</a>) Interestingly, an early postmortem study from 31 pediatric ALL patients that received native <em>E. coli</em> asparaginase found that 87% had developed steatosis after exposure to asparaginase.(<a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796452">27</a>)</p><p id="P16">We observed that ALT was higher (<a href="/pmc/articles/PMC5511775/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>, <a href="#SD13" rid="SD13" class=" supplementary-material">Table S6</a>) in those with ancestry indicating Hispanic status or whites than in blacks, as others have reported.(<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796428">11</a>) Differences in the risk allele frequency of the <em>PNPLA3</em> rs738409 variant mirrored the differences in ALT among race groups (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3B</span></a>), although this variant did not reach statistical significance in blacks or Hispanics (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figures 3A</span></a>&amp;<a href="#SD17" rid="SD17" class=" supplementary-material">S3B</a>), likely due to relatively low power because of small sample sizes for non-whites (with an effect size of 1.36 for the rs738409 variant, our power to detect a significant effect in separate GWASs of blacks and Hispanics was only 0.32 and 0.37, respectively). Although the <em>PNPLA3</em> rs738409 variant accounted for some variability in ALT across race groups, race remained a significant risk factor for ALT even after accounting for <em>PNPLA3</em> rs738409.</p><p id="P17">We found that some of the additional association of race with ALT might be due to other genetic variants. For example, black patients carrying the <em>PIGV</em> rs12748152 and <em>GREB1</em> rs149940960 variants had lower ALT levels compared to non-carriers (<a href="/pmc/articles/PMC5511775/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3C&amp;D</span></a>, <a href="#SD10" rid="SD10" class=" supplementary-material">Table S3</a>). <em>PIGV</em> rs12748152 is an expression quantitative trait locus (eQTL) for <em>PIGV</em>, <em>ARID1A</em> and <em>ZDHHC18</em>,(<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796425">28</a>, <a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796463">29</a>) and is also a QTL for cholesterol and triglycerides levels,(<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796460">30</a>) whereas <em>GREB1</em> rs149940960 is in the 3′ untranslated region (3′-UTR) of <em>GREB1,</em> which regulates circulating levels of chemoattractant protein-1 (CCL2) and insulin-like growth factor binding protein 3 (IGFBF-3).(<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796427">31</a>) High levels of the latter are associated with adiposity and insulin resistance(<a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796447">32</a>) while the former is a cytokine that recruits immune cells into damaged areas of the liver.(<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796465">33</a>) Reports suggest that infiltrating immune cells directly kill distressed hepatocytes overloaded with triglycerides. Preventing this infiltration with NF-κB inhibitors may be another possible avenue of intervention.(<a href="#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796462">34</a>) Although it has not been implicated in NAFLD, PIGV is involved in the biosynthesis of glycosylphosphatidylinositol. The <em>PIGV</em> rs12748152 variant explained 26.6% of the variability in ALT levels among black patients. However, there was no significant association in those with low West African ancestry (<em>P</em> = 0.27), and the variant was actually present at a lower frequency among blacks than other race groups (MAF = 2.0% in blacks, 13.3% in non-blacks). Limitations of these speculations lie in the small sample size of blacks in our cohort and low MAF of these genetic variants among them.</p><p id="P18">Although we think asparaginase was the most likely cause of post-induction ALT elevations in this study, we acknowledge that other elements of ALL induction therapy can also cause increases in ALT. Interestingly, high-dose methotrexate is well-known to cause acute elevations in ALT,(<a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_725128229">35</a>) but this was unlikely to have contributed to the end-of-induction ALT (which was measured 42–46 days after a single dose of methotrexate for Total XV), and because high-dose methotrexate was used prior to induction only in Total XV, not Total XVI (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>), and yet ALT was higher in patients enrolled on Total XVI compared to Total XV (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>). Likewise, although thiopurines can cause elevations in ALT, they are more prominent with mercaptopurine (used in Total XV) than with thioguanine (used in Total XVI) (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>),(<a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796450">36</a>, <a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796419">37</a>) and thus unlikely to explain the higher ALT on Total XVI compare to Total XV. The use of PEG-asparaginase at 3000 units/m<sup>2</sup> on Total XVI results in much higher and more prolonged serum asparaginase concentrations than the doses of native <em>E. coli</em> asparaginase that we used on Total XV.(<a href="#R38" rid="R38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796437">38</a>) Most tellingly, in both Total XV and Total XVI, ALT was higher in the 25% of patients who required extra doses of asparaginase due to high MRD during induction therapy than it was in those who did not receive extra doses (<a href="/pmc/articles/PMC5511775/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>).</p><p id="P19">The association of <em>PNPLA3</em> rs738409 with ALT after induction therapy was replicated in the COG AALL0232 protocol. The replication is somewhat remarkable in that there were several important factors that differed between the discovery and replication cohorts. First, patients on AALL0232 were older than those in the SJCRH discovery cohort (<a href="/pmc/articles/PMC5511775/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>), and, as expected, exhibited higher ALT grades. Second, discrete ALT values were not available for the AALL0232 cohort, only CTCAE grades; and very few cases of grade 1 and 2 ALT elevation were recorded. Thus, we used linear regression in the discovery cohort but used case (grade &gt; 2)-control (grade ≤ 2) logistic regression for the replication cohort (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S6</a>). Finally, BMI was not available for patients in AALL0232. Despite these differences, the effect of <em>PNPLA3</em> rs738409 variant was still replicated.</p><p id="P20" class="p p-last">In summary, we have identified that elevated post-induction chemotherapy ALT levels were likely due primarily to asparaginase, and we found that the same <em>PNPLA3</em> I148M variant that was previously shown to be the most important determinant of NAFLD in a general population of adults is associated with drug-induced increases in serum ALT. Together, our genetic data from patients with ALL and our preclinical data in mice suggest that hepatotoxicity caused by ALL remission-induction chemotherapy may be mediated by induction of fatty liver and that the toxicity can be modulated by inherited germline polymorphisms that affect hepatic triglyceride homeostasis.</p></div><div id="S4" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S4title">Materials and Methods</h2><div id="S5" class="sec sec-first"><h3 id="S5title">Patients</h3><p id="P21" class="p p-first">The discovery cohort consisted of patients enrolled on SJCRH protocols Total XV(<a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796444">39</a>) (n = 373, ClinicalTrials.gov identifier: <a id="__tag_724796542" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00137111" ref="reftype=extlink-clinical-trial&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00137111","term_id":"NCT00137111"}}</span>NCT00137111</a>) and Total XVI(<a href="#R40" rid="R40" class=" bibr popnode">40</a>) (n = 342, ClinicalTrials.gov identifier: <a id="__tag_724796543" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00549848" ref="reftype=extlink-clinical-trial&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00549848","term_id":"NCT00549848"}}</span>NCT00549848</a>) for newly diagnosed ALL. The replication cohort consisted of children with newly diagnosed ALL who were treated on the COG AALL0232 protocol (N = 2,285, ClinicalTrials.gov identifier: <a id="__tag_724796541" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00075725" ref="reftype=extlink-clinical-trial&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00075725","term_id":"NCT00075725"}}</span>NCT00075725</a>) for high-risk B-precursor ALL. Patients included in the genetic association analyses represented 85% (n = 715 of 840) of patients in the SJCRH discovery cohort, and 80% (n = 2285 of 2868) of participants in the COG replication cohort (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S1</a>).</p><p id="P22">Informed consent from the parents or guardians or patients, and assent from the patients, where appropriate, were obtained according to guidelines used at the Institutional Review Boards of the participating institutions. The COG AALL0232 protocol was also approved by the National Cancer Institute.</p><p id="P23" class="p p-last">For the SJCRH cohort, ALT values were graded using CTCAE version 3.0.(<a href="#R41" rid="R41" class=" bibr popnode">41</a>) ALT values between 1.0 ~ 2.5 fold of normal upper limit were assigned as grade 1, between 2.5 ~5.0 fold as grade 2, between 5.0 ~20.0 fold as grade 3, and &gt; 20.0 fold as grade 4. Patient BMI at the time of ALT sample collection was calculated and BMI percentile was determined as described previously with obesity defined as ≥ 95th percentile.(<a href="#R42" rid="R42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796433">42</a>) For the COG AALL0232 cohort, ALT values were graded using the CTCAE version 4.0. ALT values between 1.0 ~ 3.0 fold of normal upper limit were assigned as grade 1, between 3.0 ~5.0 fold as grade 2, between 5.0 ~20.0 fold as grade 3, and &gt; 20.0 fold as grade 4.</p></div><div id="S6" class="sec"><h3 id="S6title">Treatment</h3><p id="P24" class="p p-first">During induction therapy, patients enrolled on the SJCRH Total XV or Total XVI protocols received asparaginase, prednisone, vincristine, daunorubicin, cyclophosphamide, cytarabine, and thiopurine (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>).(<a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796422">39</a>, <a href="#R40" rid="R40" class=" bibr popnode">40</a>) Total XV patients received native <em>E. coli</em> asparaginase (Elspar) at 10,000 units/m<sup>2</sup> IM, three times weekly for six doses and Total XVI patients received a single dose of PEGylated <em>E. coli</em> asparaginase (Oncaspar) at 3,000 units/m<sup>2</sup> IV. Patients on Total XV with day 19 MRD ≥ 5% received three additional doses of native <em>E. coli</em> asparaginase over a week’s period, and patients on Total XVI with day 15 MRD ≥ 1% received an additional dose of PEGylated <em>E. coli</em> asparaginase (<a href="/pmc/articles/PMC5511775/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>, <a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>). Post-induction samples for ALT and total bilirubin measurement were drawn on day 46 (Total XV) and on day 42 (Total XVI) from the start of remission induction therapy, regardless of clinical suspicion of hepatotoxicity (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>). ALT and total bilirubin were also measured at diagnosis (pre-induction therapy), before the patients were exposed to methotrexate or asparaginase (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S9</a>).</p><p id="P25" class="p p-last">During induction therapy, patients enrolled on COG AALL0232 received vincristine, daunorubicin, dexamethasone or prednisone, and PEGylated <em>E. coli</em> asparaginase.(<a href="#R43" rid="R43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_725128230">43</a>) Patients with day 29 MRD between 1% and 25% received extended induction consisting of additional doses of vincristine, daunorubicin, dexamethasone or prednisone, and PEGylated <em>E. coli</em> asparaginase. During consolidation, patients received cytarabine, vincristine, cyclophosphamide, mercaptopurine, and PEGylated <em>E. coli</em> asparaginase (<a href="#SD14" rid="SD14" class=" supplementary-material">Table S7</a>). Measurement of ALT levels was a required observation on COG AALL0232 on day 1 of induction and at the start of consolidation and was performed at other times at the discretion of the treating physician. Sites were required to report all grade 3 and higher ALT elevation.</p></div><div id="S7" class="sec"><h3 id="S7title">Genotyping</h3><p id="P26" class="p p-first-last">Germline DNA was genotyped using the Exome-24 BeadChip (Illumina, San Diego, CA) (689 patients in SJCRH cohort and 2,382 in AALL0232 trial) and either the Affymetrix Genome-Wide Human SNP Array 6.0 or the Affymetrix Human Mapping 500K Array Set (839 in SJCRH cohort and 2,666 for AALL0232 trial), as described previously.(<a href="#R44" rid="R44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796454">44</a>) MaCH-Admix (<a href="http://www.unc.edu/~yunmli/MaCH-Admix" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.unc.edu/~yunmli/MaCH-Admix</a>) was used to impute the remaining untyped SNPs using the 1000 Genomes Project (<a href="http://www.1000genomes.org" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.1000genomes.org</a>) as described elsewhere.(<a href="#R45" rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796456">45</a>, <a href="#R46" rid="R46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796434">46</a>) Germline DNA from 552 patients from the SJCRH cohort was also subjected to whole exome sequencing. For this, genomic libraries were prepared using the NimbleGen SeqCap EZ Exome Enrichment Kit v2.0 (Roche NimbleGen, Madison, WI) and sequencing was performed using the HiSeq 2000 Sequencing System (Illumina, San Diego, CA). The Hardy-Weinberg equilibrium (HWE) test was performed using PLINK on SNPs with a MAF ≥ 1% and among patients of European ancestry. SNPs with genotyping call rates &lt; 95% and SNPs that were not in HWE (P values &lt; 0.001) were excluded from the association analysis (<a href="#SD17" rid="SD17" class=" supplementary-material">Figure S1</a>).</p></div><div id="S8" class="sec"><h3 id="S8title">Genetic Ancestry</h3><p id="P27" class="p p-first-last">The genetic ancestry of patients was determined using STRUCTURE (<a href="http://pritchardlab.stanford.edu/structure.html" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://pritchardlab.stanford.edu/structure.html</a>) as previously described,(<a href="#R47" rid="R47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796424">47</a>) and percent ancestry was treated as a continuous variable or used to assign patients to race groups: whites were defined as having &gt; 90% Northern European ancestry, blacks as having &gt; 70% West African ancestry, Hispanics as having Native American ancestry &gt; 10% and greater than their African ancestry percentage, Asians as having &gt; 90% East Asian ancestry, and others as those whose ancestry was outside the above boundaries. In the SJCRH cohort, patients of Asian ancestry were grouped with others due to their small sample size.</p></div><div id="S9" class="sec"><h3 id="S9title">Preclinical <em>In vivo</em> Asparaginase-induced Hepatotoxicity Studies</h3><p id="P28" class="p p-first-last">Male Balb/cJ mice (4-week-old) (Jackson Laboratories, Bar Harbor, ME) received 1,500 IU/kg of PEGylated <em>E. coli</em> asparaginase by intraperitoneal injection twice weekly for 6 weeks. Livers were collected at the end of the experiment and snap frozen in liquid nitrogen. Frozen livers were immersed in OCT media and 4 μm sections were stained with Oil-red O. The staining intensity was quantified using the Aperio Image analysis system (Aperio, Vista, CA). Three 1 mm<sup>2</sup> square regions for each sample were analyzed and the number of strongly positive pixels in the regions was used to compare experimental and control samples. All experiments involving the use of mice were approved by the Institutional Animal Care and Use Committee (IACUC) of St. Jude Children’s Research Hospital. Mice were housed in an American Association of Laboratory Animal Care-accredited facility. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).</p></div><div id="S10" class="sec sec-last"><h3 id="S10title">Data Analysis</h3><p id="P29" class="p p-first-last">Univariate and multivariate linear regression was performed using a general linear model with R statistical software (version 2.13.2) to identify clinical risk factors associated with post-induction ALT levels as a continuous variable. For the COG AALL0232 replication cohort, associations between clinical risk factors and the frequency of grade &gt; 2 hepatotoxicity were determined using Fisher’s exact test in R. The genome-wide association analysis between SNP genotypes and ALT was performed in PLINK 1.9 (<a href="https://www.cog-genomics.org/plink2" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://www.cog-genomics.org/plink2</a>) using linear or logistic regression as appropriate, adjusting for significant covariates and assuming an additive genetic model.(<a href="#R48" rid="R48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_724796420">48</a>) Within each race group defined above (whites, blacks, and Hispanics), the first five principal components were calculated using GCTA version 1.26.0 (<a href="http://cnsgenomics.com/software/gcta/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://cnsgenomics.com/software/gcta/</a>) with genotype data acquired from the Affymetrix arrays. Gene-level association was done using the sequence kernel association test (SKAT) as implemented by PLINK/SEQ (<a href="https://atgu.mgh.harvard.edu/plinkseq/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://atgu.mgh.harvard.edu/plinkseq/</a>). Linkage disequilibrium based variant pruning was performed using PLINK. To assess the proportion of variability in ALT accounted for by specific genomic variants, a general linear model was used.</p></div></div><div id="unreferenced-ft" class="tsec sec headless whole_rhythm"><div class="unreferenced">​
                    <div class="boxed-text-box whole_rhythm hide-overflow" id="BX1"><div class="caption"><h3 id="idm139879745788496title">Study Highlights</h3></div><div class="sec" id="S14"><h3 id="S14title">What is the current knowledge on the topic?</h3><p id="P31" class="p p-first-last">Hepatotoxicity is a frequent complication leading to treatment interruptions, and several drugs used in ALL remission induction are associated with the development of hepatotoxicity, including asparaginase. There are no prior genome-wide association studies for hepatotoxicity in patients with ALL.</p></div><div class="sec" id="S15"><h3 id="S15title">What question did this study address?</h3><p id="P33" class="p p-first-last">This study evaluated patient- and treatment- related variables associated with hepatotoxicity in two ancestrally diverse groups of pediatric ALL patients, using ALT levels measured at the end of remission induction as an indicator. The study identified genetic variants that contribute to the risk of hepatotoxicity on a genomic level.</p></div><div class="sec" id="S16"><h3 id="S16title">What this study adds to our knowledge?</h3><p id="P35" class="p p-first-last"><em>PNPLA3</em> rs738409 reached genome-wide significance as a risk factor of hepatotoxicity in patients that completed ALL remission induction. Asparaginase, especially in its PEGylated preparation, is likely a major contributor to higher ALT levels during this treatment phase.</p></div><div class="sec" id="S17"><h3 id="S17title">How this might change clinical pharmacology or translational science?</h3><p id="P37" class="p p-first-last">The study accentuated asparaginase hepatotoxicity during ALL induction, and identified a pharmacogenetic risk factor in this setting, <em>PNPLA3</em> rs738409, which overlaps with that for non-alcoholic fatty liver disease.</p></div></div></div></div><div id="S12" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S12title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supp TableS1</h4><div class="sup-box half_rhythm" id="d36e1265"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS1.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(13K, docx)</sup></div></div><div class="sec suppmat" id="SD2"><h4>Supp TableS10</h4><div class="sup-box half_rhythm" id="d36e1269"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS10.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(81K, tif)</sup></div></div><div class="sec suppmat" id="SD3"><h4>Supp TableS11</h4><div class="sup-box half_rhythm" id="d36e1273"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS11.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(137K, tif)</sup></div></div><div class="sec suppmat" id="SD4"><h4>Supp TableS12</h4><div class="sup-box half_rhythm" id="d36e1277"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS12.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(73K, tif)</sup></div></div><div class="sec suppmat" id="SD5"><h4>Supp TableS13</h4><div class="sup-box half_rhythm" id="d36e1281"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS13.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(75K, tif)</sup></div></div><div class="sec suppmat" id="SD6"><h4>Supp TableS14</h4><div class="sup-box half_rhythm" id="d36e1285"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS14.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(405K, tif)</sup></div></div><div class="sec suppmat" id="SD7"><h4>Supp TableS15</h4><div class="sup-box half_rhythm" id="d36e1289"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS15.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(95K, tif)</sup></div></div><div class="sec suppmat" id="SD8"><h4>Supp TableS16</h4><div class="sup-box half_rhythm" id="d36e1293"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS16.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(135K, tif)</sup></div></div><div class="sec suppmat" id="SD9"><h4>Supp TableS2</h4><div class="sup-box half_rhythm" id="d36e1297"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS2.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16K, docx)</sup></div></div><div class="sec suppmat" id="SD10"><h4>Supp TableS3</h4><div class="sup-box half_rhythm" id="d36e1301"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS3.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16K, docx)</sup></div></div><div class="sec suppmat" id="SD11"><h4>Supp TableS4</h4><div class="sup-box half_rhythm" id="d36e1306"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS4.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16K, docx)</sup></div></div><div class="sec suppmat" id="SD12"><h4>Supp TableS5</h4><div class="sup-box half_rhythm" id="d36e1310"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS5.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(16K, docx)</sup></div></div><div class="sec suppmat" id="SD13"><h4>Supp TableS6</h4><div class="sup-box half_rhythm" id="d36e1314"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS6.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(13K, docx)</sup></div></div><div class="sec suppmat" id="SD14"><h4>Supp TableS7</h4><div class="sup-box half_rhythm" id="d36e1318"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS7.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(13K, docx)</sup></div></div><div class="sec suppmat" id="SD15"><h4>Supp TableS8</h4><div class="sup-box half_rhythm" id="d36e1322"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS8.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(154K, tif)</sup></div></div><div class="sec suppmat" id="SD16"><h4>Supp TableS9</h4><div class="sup-box half_rhythm" id="d36e1326"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Supp_TableS9.tif" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(208K, tif)</sup></div></div><div class="sec suppmat" id="SD17"><h4>Suppinfo</h4><div class="sup-box half_rhythm" id="d36e1330"><a href="/pmc/articles/PMC5511775/bin/NIHMS843060-supplement-Suppinfo.docx" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(36K, docx)</sup></div></div></div><div id="S13" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S13title">Acknowledgments</h2><div class="sec"><p id="__p2">This study was supported by grants GM 1152579, CA 21765, CA 156449, CA 142665, CA 36401, U10 CA98543 (COG Chair’s grant), U10 CA98413 (COG Statistical Center), and U24 <a id="__tag_805637715" class="tag_hotlink" href="/nuccore/CA114766" ref="/nuccore/CA114766"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"CA114766","term_id":"34968073","term_text":"CA114766"}}</span>CA114766</a> (COG Specimen Banking) from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities. S.P.H is the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics at the Children’s Hospital of Philadelphia.</p></div></div><div id="idm139879736933136" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139879736933136title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN3"></p><p id="__p3" class="p p-first"><strong>Conflict of Interest</strong></p><p id="__p4" class="p p-last">The authors have no conflicts of interest to disclose.</p><p></p><div><p id="__p5" class="p p-first"><strong>Authorship Contribution</strong></p>M.V.R., Y.L., C.A.F., C.S., W.Y., C.C., C.P., N.K., C.L., L.R., S.E.K., L.J.J., E.C.L., N.W., W.L.C., M.L.L., E.A.R., S.P.H., M.D., J.J.Y., C.G.M., J.Z., W.E.E., S.J., and C-H.P. wrote the manuscript; M.V.R., Y.L., and C.A.F. designed the research; Y.L. and C.A.F. performed the research; M.V.R., Y.L., C.A.F., C.S., W.Y., and C.C. analyzed the data.</div></div></div><div id="idm139879742670496" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm139879742670496title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <span><span class="ref-journal">Journal of clinical oncology : official journal of the American Society of Clinical Oncology. </span>2015;<span class="ref-vol">33</span>(27):2938–48.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4567699/">PMC free article</a>]</span> [<a href="/pubmed/26304874" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology+:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Childhood+Acute+Lymphoblastic+Leukemia:+Progress+Through+Collaboration&amp;author=CH+Pui&amp;author=JJ+Yang&amp;author=SP+Hunger&amp;author=R+Pieters&amp;author=M+Schrappe&amp;volume=33&amp;issue=27&amp;publication_year=2015&amp;pages=2938-48&amp;pmid=26304874&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>(5):1211–8.</span> [<a href="/pubmed/11222362" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Improved+outcome+for+children+with+acute+lymphoblastic+leukemia:+results+of+Dana-Farber+Consortium+Protocol+91–01&amp;author=LB+Silverman&amp;author=RD+Gelber&amp;author=VK+Dalton&amp;author=BL+Asselin&amp;author=RD+Barr&amp;volume=97&amp;issue=5&amp;publication_year=2001&amp;pages=1211-8&amp;pmid=11222362&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. <span><span class="ref-journal">British journal of cancer. </span>1990;<span class="ref-vol">61</span>(5):767–72.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1971607/">PMC free article</a>]</span> [<a href="/pubmed/2337515" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+journal+of+cancer&amp;title=Prognostic+significance+of+hepatotoxicity+during+maintenance+chemotherapy+for+childhood+acute+lymphoblastic+leukaemia&amp;author=K+Schmiegelow&amp;author=M+Pulczynska&amp;volume=61&amp;issue=5&amp;publication_year=1990&amp;pages=767-72&amp;pmid=2337515&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, et al.  Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. <span><span class="ref-journal">British journal of clinical pharmacology. </span>2011;<span class="ref-vol">71</span>(4):575–84.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3080646/">PMC free article</a>]</span> [<a href="/pubmed/21395650" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+journal+of+clinical+pharmacology&amp;title=Determinants+of+mercaptopurine+toxicity+in+paediatric+acute+lymphoblastic+leukemia+maintenance+therapy&amp;author=T+Adam+de+Beaumais&amp;author=M+Fakhoury&amp;author=Y+Medard&amp;author=S+Azougagh&amp;author=D+Zhang&amp;volume=71&amp;issue=4&amp;publication_year=2011&amp;pages=575-84&amp;pmid=21395650&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, et al.  A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL) <span><span class="ref-journal">Cancer. </span>2010;<span class="ref-vol">116</span>(2):506–13.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3542639/">PMC free article</a>]</span> [<a href="/pubmed/20014183" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=A+randomized,+controlled,+double-blind,+pilot+study+of+milk+thistle+for+the+treatment+of+hepatotoxicity+in+childhood+acute+lymphoblastic+leukemia+(ALL)&amp;author=EJ+Ladas&amp;author=DJ+Kroll&amp;author=NH+Oberlies&amp;author=B+Cheng&amp;author=DH+Ndao&amp;volume=116&amp;issue=2&amp;publication_year=2010&amp;pages=506-13&amp;pmid=20014183&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Journal of clinical oncology : official journal of the American Society of Clinical Oncology. </span>1997;<span class="ref-vol">15</span>(4):1560–6.</span> [<a href="/pubmed/9193353" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology+:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Serum+aminotransferase+elevation+during+and+following+treatment+of+childhood+acute+lymphoblastic+leukemia&amp;author=AC+Farrow&amp;author=GR+Buchanan&amp;author=RJ+Zwiener&amp;author=WP+Bowman&amp;author=NJ+Winick&amp;volume=15&amp;issue=4&amp;publication_year=1997&amp;pages=1560-6&amp;pmid=9193353&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. <span><span class="ref-journal">Pediatric clinics of North America. </span>2015;<span class="ref-vol">62</span>(1):61–73.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4366417/">PMC free article</a>]</span> [<a href="/pubmed/25435112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatric+clinics+of+North+America&amp;title=Treatment+of+pediatric+acute+lymphoblastic+leukemia&amp;author=SL+Cooper&amp;author=PA+Brown&amp;volume=62&amp;issue=1&amp;publication_year=2015&amp;pages=61-73&amp;pmid=25435112&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, et al.  Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <span><span class="ref-journal">Leukemia &amp; lymphoma. </span>2011;<span class="ref-vol">52</span>(12):2237–53.</span> [<a href="/pubmed/21827361" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia+&amp;+lymphoma&amp;title=Prevention+and+management+of+asparaginase/pegasparaginase-associated+toxicities+in+adults+and+older+adolescents:+recommendations+of+an+expert+panel&amp;author=W+Stock&amp;author=D+Douer&amp;author=DJ+DeAngelo&amp;author=M+Arellano&amp;author=A+Advani&amp;volume=52&amp;issue=12&amp;publication_year=2011&amp;pages=2237-53&amp;pmid=21827361&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. <span><span class="ref-journal">Annals of hematology. </span>1996;<span class="ref-vol">72</span>(4):194–201.</span> [<a href="/pubmed/8624372" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+hematology&amp;title=High-dose+methotrexate+in+the+treatment+of+adult+acute+lymphoblastic+leukemia&amp;author=N+Gokbuget&amp;author=D+Hoelzer&amp;volume=72&amp;issue=4&amp;publication_year=1996&amp;pages=194-201&amp;pmid=8624372&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al.  Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. <span><span class="ref-journal">Nature genetics. </span>2011;<span class="ref-vol">43</span>(11):1131–8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3482372/">PMC free article</a>]</span> [<a href="/pubmed/22001757" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Genome-wide+association+study+identifies+loci+influencing+concentrations+of+liver+enzymes+in+plasma&amp;author=JC+Chambers&amp;author=W+Zhang&amp;author=J+Sehmi&amp;author=X+Li&amp;author=MN+Wass&amp;volume=43&amp;issue=11&amp;publication_year=2011&amp;pages=1131-8&amp;pmid=22001757&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, et al.  Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. <span><span class="ref-journal">Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. </span>2013;<span class="ref-vol">11</span>(9):1183–90. e2.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4197011/">PMC free article</a>]</span> [<a href="/pubmed/23416328" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+gastroenterology+and+hepatology+:+the+official+clinical+practice+journal+of+the+American+Gastroenterological+Association&amp;title=Association+between+variants+in+or+near+PNPLA3,+GCKR,+and+PPP1R3B+with+ultrasound-defined+steatosis+based+on+data+from+the+third+National+Health+and+Nutrition+Examination+Survey&amp;author=R+Hernaez&amp;author=J+McLean&amp;author=M+Lazo&amp;author=FL+Brancati&amp;author=JN+Hirschhorn&amp;volume=11&amp;issue=9&amp;publication_year=2013&amp;pages=1183-90&amp;pmid=23416328&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. <span><span class="ref-journal">Nature genetics. </span>2008;<span class="ref-vol">40</span>(12):1461–5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2597056/">PMC free article</a>]</span> [<a href="/pubmed/18820647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Genetic+variation+in+PNPLA3+confers+susceptibility+to+nonalcoholic+fatty+liver+disease&amp;author=S+Romeo&amp;author=J+Kozlitina&amp;author=C+Xing&amp;author=A+Pertsemlidis&amp;author=D+Cox&amp;volume=40&amp;issue=12&amp;publication_year=2008&amp;pages=1461-5&amp;pmid=18820647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. <span><span class="ref-journal">Science. </span>2011;<span class="ref-vol">332</span>(6037):1519–23.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3229276/">PMC free article</a>]</span> [<a href="/pubmed/21700865" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Human+fatty+liver+disease:+old+questions+and+new+insights&amp;author=JC+Cohen&amp;author=JD+Horton&amp;author=HH+Hobbs&amp;volume=332&amp;issue=6037&amp;publication_year=2011&amp;pages=1519-23&amp;pmid=21700865&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. <span><span class="ref-journal">PLoS genetics. </span>2011;<span class="ref-vol">7</span>(3):e1001324.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3053321/">PMC free article</a>]</span> [<a href="/pubmed/21423719" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+genetics&amp;title=Genome-wide+association+analysis+identifies+variants+associated+with+nonalcoholic+fatty+liver+disease+that+have+distinct+effects+on+metabolic+traits&amp;author=EK+Speliotes&amp;author=LM+Yerges-Armstrong&amp;author=J+Wu&amp;author=R+Hernaez&amp;author=LJ+Kim&amp;volume=7&amp;issue=3&amp;publication_year=2011&amp;pages=e1001324&amp;pmid=21423719&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al.  Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. <span><span class="ref-journal">Human genetics. </span>2013;<span class="ref-vol">132</span>(7):783–92.</span> [<a href="/pubmed/23535911" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Human+genetics&amp;title=Genome-wide+scan+revealed+that+polymorphisms+in+the+PNPLA3,+SAMM50,+and+PARVB+genes+are+associated+with+development+and+progression+of+nonalcoholic+fatty+liver+disease+in+Japan&amp;author=T+Kitamoto&amp;author=A+Kitamoto&amp;author=M+Yoneda&amp;author=H+Hyogo&amp;author=H+Ochi&amp;volume=132&amp;issue=7&amp;publication_year=2013&amp;pages=783-92&amp;pmid=23535911&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al.  Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. <span><span class="ref-journal">PloS one. </span>2012;<span class="ref-vol">7</span>(6):e38322.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3375283/">PMC free article</a>]</span> [<a href="/pubmed/22719876" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PloS+one&amp;title=Genetic+polymorphisms+of+the+human+PNPLA3+gene+are+strongly+associated+with+severity+of+non-alcoholic+fatty+liver+disease+in+Japanese&amp;author=T+Kawaguchi&amp;author=Y+Sumida&amp;author=A+Umemura&amp;author=K+Matsuo&amp;author=M+Takahashi&amp;volume=7&amp;issue=6&amp;publication_year=2012&amp;pages=e38322&amp;pmid=22719876&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>(6):1883–94.</span> [<a href="/pubmed/21381068" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Meta-analysis+of+the+influence+of+I148M+variant+of+patatin-like+phospholipase+domain+containing+3+gene+(PNPLA3)+on+the+susceptibility+and+histological+severity+of+nonalcoholic+fatty+liver+disease&amp;author=S+Sookoian&amp;author=CJ+Pirola&amp;volume=53&amp;issue=6&amp;publication_year=2011&amp;pages=1883-94&amp;pmid=21381068&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, et al.  Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>(3):791–9.</span> [<a href="/pubmed/21319195" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Patatin-like+phospholipase+domain-containing+3+I148M+polymorphism,+steatosis,+and+liver+damage+in+chronic+hepatitis+C&amp;author=L+Valenti&amp;author=M+Rumi&amp;author=E+Galmozzi&amp;author=A+Aghemo&amp;author=B+Del+Menico&amp;volume=53&amp;issue=3&amp;publication_year=2011&amp;pages=791-9&amp;pmid=21319195&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>(5):1776.</span> author reply 7. [<a href="/pubmed/21351112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Patatin-like+phospholipase+domain+containing+3+sequence+variant+and+hepatocellular+carcinoma&amp;author=SG+Corradini&amp;author=MA+Burza&amp;author=A+Molinaro&amp;author=S+Romeo&amp;volume=53&amp;issue=5&amp;publication_year=2011&amp;pages=1776&amp;pmid=21351112&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al.  The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. <span><span class="ref-journal">Liver international : official journal of the International Association for the Study of the Liver. </span>2011;<span class="ref-vol">31</span>(9):1326–31.</span> [<a href="/pubmed/21745282" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Liver+international+:+official+journal+of+the+International+Association+for+the+Study+of+the+Liver&amp;title=The+PNPLA3+I148M+polymorphism+is+associated+with+insulin+resistance+and+nonalcoholic+fatty+liver+disease+in+a+normoglycaemic+population&amp;author=CW+Wang&amp;author=HY+Lin&amp;author=SJ+Shin&amp;author=ML+Yu&amp;author=ZY+Lin&amp;volume=31&amp;issue=9&amp;publication_year=2011&amp;pages=1326-31&amp;pmid=21745282&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Maranville JC, Cox NJ. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. <span><span class="ref-journal">The pharmacogenomics journal. </span>2015</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4704992/">PMC free article</a>]</span> [<a href="/pubmed/26149738" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+pharmacogenomics+journal&amp;title=Pharmacogenomic+variants+have+larger+effect+sizes+than+genetic+variants+associated+with+other+dichotomous+complex+traits&amp;author=JC+Maranville&amp;author=NJ+Cox&amp;publication_year=2015&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Segal I, Rassekh SR, Bond MC, Senger C, Schreiber RA. Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. <span><span class="ref-journal">Pediatric blood &amp; cancer. </span>2010;<span class="ref-vol">55</span>(3):434–9.</span> [<a href="/pubmed/20658613" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pediatric+blood+&amp;+cancer&amp;title=Abnormal+liver+transaminases+and+conjugated+hyperbilirubinemia+at+presentation+of+acute+lymphoblastic+leukemia&amp;author=I+Segal&amp;author=SR+Rassekh&amp;author=MC+Bond&amp;author=C+Senger&amp;author=RA+Schreiber&amp;volume=55&amp;issue=3&amp;publication_year=2010&amp;pages=434-9&amp;pmid=20658613&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. <span><span class="ref-journal">Journal of lipid research. </span>2009;<span class="ref-vol">50</span>(Suppl):S63–8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2674697/">PMC free article</a>]</span> [<a href="/pubmed/19029121" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+lipid+research&amp;title=Mammalian+patatin+domain+containing+proteins:+a+family+with+diverse+lipolytic+activities+involved+in+multiple+biological+functions&amp;author=PC+Kienesberger&amp;author=M+Oberer&amp;author=A+Lass&amp;author=R+Zechner&amp;volume=50&amp;issue=Suppl&amp;publication_year=2009&amp;pages=S63-8&amp;pmid=19029121&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. <span><span class="ref-journal">The Journal of biological chemistry. </span>2011;<span class="ref-vol">286</span>(43):37085–93.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3199456/">PMC free article</a>]</span> [<a href="/pubmed/21878620" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=The+Journal+of+biological+chemistry&amp;title=Expression+and+characterization+of+a+PNPLA3+protein+isoform+(I148M)+associated+with+nonalcoholic+fatty+liver+disease&amp;author=Y+Huang&amp;author=JC+Cohen&amp;author=HH+Hobbs&amp;volume=286&amp;issue=43&amp;publication_year=2011&amp;pages=37085-93&amp;pmid=21878620&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, et al.  Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">61</span>(1):108–18.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4262735/">PMC free article</a>]</span> [<a href="/pubmed/24917523" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Pnpla3I148M+knockin+mice+accumulate+PNPLA3+on+lipid+droplets+and+develop+hepatic+steatosis&amp;author=E+Smagris&amp;author=S+BasuRay&amp;author=J+Li&amp;author=Y+Huang&amp;author=KM+Lai&amp;volume=61&amp;issue=1&amp;publication_year=2015&amp;pages=108-18&amp;pmid=24917523&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, et al.  Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. <span><span class="ref-journal">European journal of haematology. </span>2015</span> [<a href="/pubmed/26095294" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+journal+of+haematology&amp;title=Toxicity+profile+of+repeated+doses+of+PEG-asparaginase+incorporated+into+a+pediatric-type+regimen+for+adult+acute+lymphoblastic+leukemia&amp;author=I+Aldoss&amp;author=D+Douer&amp;author=CE+Behrendt&amp;author=P+Chaudhary&amp;author=A+Mohrbacher&amp;publication_year=2015&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. <span><span class="ref-journal">Cancer. </span>1971;<span class="ref-vol">28</span>(2):361–4.</span> [<a href="/pubmed/5109448" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Duration+and+severity+of+fatty+metamorphosis+of+the+liver+following+L-asparaginase+therapy&amp;author=CB+Pratt&amp;author=WW+Johnson&amp;volume=28&amp;issue=2&amp;publication_year=1971&amp;pages=361-4&amp;pmid=5109448&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al.  Systematic identification of trans eQTLs as putative drivers of known disease associations. <span><span class="ref-journal">Nature genetics. </span>2013;<span class="ref-vol">45</span>(10):1238–43.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3991562/">PMC free article</a>]</span> [<a href="/pubmed/24013639" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Systematic+identification+of+trans+eQTLs+as+putative+drivers+of+known+disease+associations&amp;author=HJ+Westra&amp;author=MJ+Peters&amp;author=T+Esko&amp;author=H+Yaghootkar&amp;author=C+Schurmann&amp;volume=45&amp;issue=10&amp;publication_year=2013&amp;pages=1238-43&amp;pmid=24013639&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Consortium GT. The Genotype-Tissue Expression (GTEx) project. <span><span class="ref-journal">Nature genetics. </span>2013;<span class="ref-vol">45</span>(6):580–5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4010069/">PMC free article</a>]</span> [<a href="/pubmed/23715323" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=The+Genotype-Tissue+Expression+(GTEx)+project&amp;volume=45&amp;issue=6&amp;publication_year=2013&amp;pages=580-5&amp;pmid=23715323&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Global Lipids Genetics C, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al.  Discovery and refinement of loci associated with lipid levels. <span><span class="ref-journal">Nature genetics. </span>2013;<span class="ref-vol">45</span>(11):1274–83.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3838666/">PMC free article</a>]</span> [<a href="/pubmed/24097068" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Discovery+and+refinement+of+loci+associated+with+lipid+levels&amp;author=C+Global+Lipids+Genetics&amp;author=CJ+Willer&amp;author=EM+Schmidt&amp;author=S+Sengupta&amp;author=GM+Peloso&amp;volume=45&amp;issue=11&amp;publication_year=2013&amp;pages=1274-83&amp;pmid=24097068&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al.  Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. <span><span class="ref-journal">PloS one. </span>2012;<span class="ref-vol">7</span>(12):e51954.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3522587/">PMC free article</a>]</span> [<a href="/pubmed/23251661" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PloS+one&amp;title=Novel+genetic+loci+identified+for+the+pathophysiology+of+childhood+obesity+in+the+Hispanic+population&amp;author=AG+Comuzzie&amp;author=SA+Cole&amp;author=SL+Laston&amp;author=VS+Voruganti&amp;author=K+Haack&amp;volume=7&amp;issue=12&amp;publication_year=2012&amp;pages=e51954&amp;pmid=23251661&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Runchey SS, Boyko EJ, Ioannou GN, Utzschneider KM. Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. <span><span class="ref-journal">Journal of gastroenterology and hepatology. </span>2014;<span class="ref-vol">29</span>(3):589–96.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3982202/">PMC free article</a>]</span> [<a href="/pubmed/24716226" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+gastroenterology+and+hepatology&amp;title=Relationship+between+serum+circulating+insulin-like+growth+factor-1+and+liver+fat+in+the+United+States&amp;author=SS+Runchey&amp;author=EJ+Boyko&amp;author=GN+Ioannou&amp;author=KM+Utzschneider&amp;volume=29&amp;issue=3&amp;publication_year=2014&amp;pages=589-96&amp;pmid=24716226&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Degre D, Lemmers A, Gustot T, Ouziel R, Trepo E, Demetter P, et al.  Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. <span><span class="ref-journal">Clinical and experimental immunology. </span>2012;<span class="ref-vol">169</span>(3):302–10.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3445007/">PMC free article</a>]</span> [<a href="/pubmed/22861370" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+and+experimental+immunology&amp;title=Hepatic+expression+of+CCL2+in+alcoholic+liver+disease+is+associated+with+disease+severity+and+neutrophil+infiltrates&amp;author=D+Degre&amp;author=A+Lemmers&amp;author=T+Gustot&amp;author=R+Ouziel&amp;author=E+Trepo&amp;volume=169&amp;issue=3&amp;publication_year=2012&amp;pages=302-10&amp;pmid=22861370&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al.  Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">51</span>(6):1998–2007.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2920131/">PMC free article</a>]</span> [<a href="/pubmed/20512988" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Accumulation+of+natural+killer+T+cells+in+progressive+nonalcoholic+fatty+liver+disease&amp;author=WK+Syn&amp;author=YH+Oo&amp;author=TA+Pereira&amp;author=GF+Karaca&amp;author=Y+Jung&amp;volume=51&amp;issue=6&amp;publication_year=2010&amp;pages=1998-2007&amp;pmid=20512988&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Weber BL, Tanyer G, Poplack DG, Reaman GH, Feusner JH, Miser JS, et al.  Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. <span><span class="ref-journal">NCIMonogr. </span>1987:207–12.</span> [<a href="/pubmed/3481038" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=NCIMonogr&amp;title=Transient+acute+hepatotoxicity+of+high-dose+methotrexate+therapy+during+childhood&amp;author=BL+Weber&amp;author=G+Tanyer&amp;author=DG+Poplack&amp;author=GH+Reaman&amp;author=JH+Feusner&amp;publication_year=1987&amp;pages=207-12&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? <span><span class="ref-journal">British journal of cancer. </span>1993;<span class="ref-vol">68</span>(1):186–90.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1968314/">PMC free article</a>]</span> [<a href="/pubmed/8318412" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=British+journal+of+cancer&amp;title=Is+6-thioguanine+more+appropriate+than+6-mercaptopurine+for+children+with+acute+lymphoblastic+leukaemia?&amp;author=L+Lennard&amp;author=HA+Davies&amp;author=JS+Lilleyman&amp;volume=68&amp;issue=1&amp;publication_year=1993&amp;pages=186-90&amp;pmid=8318412&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="element-citation">Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. <span><span class="ref-journal">Toxicology in vitro : an international journal published in association with BIBRA. </span>2008;<span class="ref-vol">22</span>(3):632–42.</span> [<a href="/pubmed/18222062" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicology+in+vitro+:+an+international+journal+published+in+association+with+BIBRA&amp;title=Differential+toxic+effects+of+azathioprine,+6-mercaptopurine+and+6-thioguanine+on+human+hepatocytes&amp;author=E+Petit&amp;author=S+Langouet&amp;author=H+Akhdar&amp;author=C+Nicolas-Nicolaz&amp;author=A+Guillouzo&amp;volume=22&amp;issue=3&amp;publication_year=2008&amp;pages=632-42&amp;pmid=18222062&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="element-citation">Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) <span><span class="ref-journal">Oncologist. </span>2007;<span class="ref-vol">12</span>(8):991–8.</span> [<a href="/pubmed/17766659" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=FDA+drug+approval+summary:+pegaspargase+(oncaspar)+for+the+first-line+treatment+of+children+with+acute+lymphoblastic+leukemia+(ALL)&amp;author=PA+Dinndorf&amp;author=J+Gootenberg&amp;author=MH+Cohen&amp;author=P+Keegan&amp;author=R+Pazdur&amp;volume=12&amp;issue=8&amp;publication_year=2007&amp;pages=991-8&amp;pmid=17766659&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="element-citation">Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">360</span>(26):2730–41.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2754320/">PMC free article</a>]</span> [<a href="/pubmed/19553647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Treating+childhood+acute+lymphoblastic+leukemia+without+cranial+irradiation&amp;author=CH+Pui&amp;author=D+Campana&amp;author=D+Pei&amp;author=WP+Bowman&amp;author=JT+Sandlund&amp;volume=360&amp;issue=26&amp;publication_year=2009&amp;pages=2730-41&amp;pmid=19553647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="element-citation">Pui CHCD, Sandlund JT, Bhojwani D, Evans WE, Relling MV, Jeha S. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. <span><span class="ref-journal">Annals of hematology. </span>2011;<span class="ref-vol">90</span>(Suppl 1):S61–3.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+hematology&amp;title=Treatment+of+childhood+acute+lymphoblastic+leukemia+without+cranial+irradiation&amp;author=CHCD+Pui&amp;author=JT+Sandlund&amp;author=D+Bhojwani&amp;author=WE+Evans&amp;author=MV+Relling&amp;volume=90&amp;issue=Suppl+1&amp;publication_year=2011&amp;pages=S61-3&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="element-citation">National Cancer Institute. <span><span class="ref-journal">Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 3.0. </span>2006 Aug;</span> Available from:  <a href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm</a>.</span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="element-citation">Inaba H, Surprise HC, Pounds S, Cao X, Howard SC, Ringwald-Smith K, et al.  Effect of body mass index on the outcome of children with acute myeloid leukemia. <span><span class="ref-journal">Cancer. </span>2012;<span class="ref-vol">118</span>(23):5989–96.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3434283/">PMC free article</a>]</span> [<a href="/pubmed/22648558" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Effect+of+body+mass+index+on+the+outcome+of+children+with+acute+myeloid+leukemia&amp;author=H+Inaba&amp;author=HC+Surprise&amp;author=S+Pounds&amp;author=X+Cao&amp;author=SC+Howard&amp;volume=118&amp;issue=23&amp;publication_year=2012&amp;pages=5989-96&amp;pmid=22648558&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="element-citation">Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232. <span><span class="ref-journal">Journal of clinical oncology : official journal of the American Society of Clinical Oncology. </span>2016</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4981974/">PMC free article</a>]</span> [<a href="/pubmed/27114587" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+clinical+oncology+:+official+journal+of+the+American+Society+of+Clinical+Oncology&amp;title=Dexamethasone+and+High-Dose+Methotrexate+Improve+Outcome+for+Children+and+Young+Adults+With+High-Risk+B-Acute+Lymphoblastic+Leukemia:+A+Report+From+Children’s+Oncology+Group+Study+AALL0232&amp;author=EC+Larsen&amp;author=M+Devidas&amp;author=S+Chen&amp;author=WL+Salzer&amp;author=EA+Raetz&amp;publication_year=2016&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="element-citation">Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Nature genetics. </span>2009;<span class="ref-vol">41</span>(9):1001–5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2762391/">PMC free article</a>]</span> [<a href="/pubmed/19684603" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Germline+genomic+variants+associated+with+childhood+acute+lymphoblastic+leukemia&amp;author=LR+Trevino&amp;author=W+Yang&amp;author=D+French&amp;author=SP+Hunger&amp;author=WL+Carroll&amp;volume=41&amp;issue=9&amp;publication_year=2009&amp;pages=1001-5&amp;pmid=19684603&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="element-citation">Liu EY, Li M, Wang W, Li Y. MaCH-admix: genotype imputation for admixed populations. <span><span class="ref-journal">Genetic epidemiology. </span>2013;<span class="ref-vol">37</span>(1):25–37.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3524415/">PMC free article</a>]</span> [<a href="/pubmed/23074066" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genetic+epidemiology&amp;title=MaCH-admix:+genotype+imputation+for+admixed+populations&amp;author=EY+Liu&amp;author=M+Li&amp;author=W+Wang&amp;author=Y+Li&amp;volume=37&amp;issue=1&amp;publication_year=2013&amp;pages=25-37&amp;pmid=23074066&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R46">46. <span class="element-citation">Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, et al.  Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>(15):1770–6.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4600016/">PMC free article</a>]</span> [<a href="/pubmed/26265699" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Genetics+of+glucocorticoid-associated+osteonecrosis+in+children+with+acute+lymphoblastic+leukemia&amp;author=SE+Karol&amp;author=W+Yang&amp;author=SL+Van+Driest&amp;author=TY+Chang&amp;author=S+Kaste&amp;volume=126&amp;issue=15&amp;publication_year=2015&amp;pages=1770-6&amp;pmid=26265699&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R47">47. <span class="element-citation">Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, et al.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <span><span class="ref-journal">Nature genetics. </span>2011;<span class="ref-vol">43</span>(3):237–41.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3104508/">PMC free article</a>]</span> [<a href="/pubmed/21297632" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+genetics&amp;title=Ancestry+and+pharmacogenomics+of+relapse+in+acute+lymphoblastic+leukemia&amp;author=JJ+Yang&amp;author=C+Cheng&amp;author=M+Devidas&amp;author=X+Cao&amp;author=Y+Fan&amp;volume=43&amp;issue=3&amp;publication_year=2011&amp;pages=237-41&amp;pmid=21297632&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R48">48. <span class="element-citation">Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>(3):559–75.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+a+tool+set+for+whole-genome+association+and+population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;author=L+Thomas&amp;author=MA+Ferreira&amp;volume=81&amp;issue=3&amp;publication_year=2007&amp;pages=559-75&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=5511775&amp;issue-id=295358&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm139879747244656title">Abstract</a></li><li><a href="#S1title">Introduction</a></li><li><a href="#S2title">Results</a></li><li><a href="#S3title">Discussion</a></li><li><a href="#S4title">Materials and Methods</a></li><li><a href="#S12title">Supplementary Material</a></li><li><a href="#S13title">Acknowledgments</a></li><li><a href="#idm139879736933136title">Footnotes</a></li><li><a href="#idm139879742670496title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC5511775/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC5511775/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC5511775/pdf/nihms843060.pdf">PDF (733K)</a></li> | <li><a href="#" data-citationid="PMC5511775" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5511775%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5511775%2F&amp;text=Genome-wide%20study%20links%20PNPLA3%20variant%20with%20elevated%20hepatic%20transaminase%20after%20acute%20lymphoblastic%20leukemia%20therapy" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5511775%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="28090653" data-aiid="5511775" data-aid="5511775" data-iid="295358" data-domainid="319" data-domain="nihpa" data-accid="PMC5511775" data-md5="02a5dafdafdf89019baa26ad9a8356a5"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T15:40:07-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal106&amp;ncbi_phid=CE8DE011DD5A20210000000001A600F7&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5511775%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC5511775/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>